

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 March 2003 (27.03.2003)

PCT

(10) International Publication Number
WO 03/024478 A1

(51) International Patent Classification⁷: A61K 38/18, 48/00, A61P 25/00

(74) Agents: MACLEAN, Martin, Robert et al.; Mathys & Squire, 100 Gray's Inn Road, London WC1X 8AL (GB).

(21) International Application Number: PCT/IB02/03998

(22) International Filing Date:
19 September 2002 (19.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/323,381 19 September 2001 (19.09.2001) US
60/326,044 28 September 2001 (28.09.2001) US

(71) Applicant (for all designated States except US): NEURONOVA AB [SE/SE]; Fiskartorpsvägen 15A-D, S-114 33 Stockholm (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DELFANI, Kioumars [SE/SE]; Pjashbacken 32,, S-174 58 Sundbyberg (SE). JANSON, Ann, Marie [SE/SE]; Floragatan 5, S-114 31 Stockholm (SE). KUHN, Georg, H. [DE/DE]; Kapellenplatz 8a, 93186 Pattendorf (DE). PLATE, Karl-heinz [DE/DE]; Humboldtstr. 84, 60318 Frankfurt (DE). SCHANZER, Anne [DE/DE]; Lenaustrasse 78, 60318 Frankfurt/Main (DE). WACHS, Frank-Peter [DE/DE]; Am Bergacker 26, 93083 Obertraubling (DE). ZHAO, Ming [CN/SE]; Arnebergatan 32, S-171 71 Solna (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/024478 A1

(54) Title: TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY USE OF PDGF OR VEGF

(57) Abstract: The invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to a reagent that modulates the proliferation, migration, differentiation and survival of central nervous system cells. These methods are useful for reducing at least one symptom of the disorder. The reagent used is platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), a combination of both, a PDGF agonist or a VEGF agonist.

TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY USE OF PDGF OR VEGF

FIELD OF THE INVENTION

5 The invention relates generally to methods of influencing neural stem cells and neural progenitor cells to produce progeny that can replace damaged or missing neurons. More specifically, the invention includes methods of exposing a patient suffering from a disorder to a reagent that regulates the proliferation, migration, differentiation and survival of central nervous system cells via modulation of PDGF or VEGF signalling. These methods are useful
10 for reducing at least one symptom of the disorder.

BACKGROUND OF THE INVENTION

15 The mammalian nervous system comprises a peripheral nervous system (PNS) and a central nervous system (CNS, comprising the brain and spinal cord), and is composed of two principal classes of cells: neurons and glial cells. The glial cells fill the spaces between neurons, nourishing them and modulating their function. Certain glial cells, such as Schwann cells in the PNS and oligodendrocytes in the CNS, also provide a myelin sheath that surrounds neural processes. The myelin sheath enables rapid conduction along the neuron.
20 In the peripheral nervous system, axons of multiple neurons may bundle together in order to form a nerve fiber. These, in turn, may be combined into fascicles or bundles.

It has been established that neural stem cells (NSCs) exist in the adult mammalian brain. This fact is of particular importance since the adult brain was thought to have very limited regenerative capacity. New neurons are continuously added to specific regions of the adult mammalian CNS. These neurons are derived from multipotent stem cells that originate from the ependymal layer in the lateral ventricular wall (Johansson et al., *Cell* 96:25-34 (1999)). Ependymal cells give rise to proliferating cells in the subventricular zone of the ventricle wall, which in turn form neuroblasts. Following migration and differentiation the neuroblasts generate neurons. NSCs also exist in the hippocampal dentate gyrus (Gould et al., *Biol. Psychiatry* 48:715-720 (2000)). Recently it was demonstrated that the human lateral ventricle and the hippocampus also harbor stem cells capable of generating neurons and glia (Johansson et al., *Exp Cell Research* 253:733-736 (1999)). The use of adult derived stem cells for tissue repair may help to overcome the ethical problems of embryonic cell research.

The role of stem cells in the adult is to replace cells that are lost by natural cell death, injury or disease. The identifying feature of a stem cell is its ability to exhibit self-renewal or to generate more of itself and, therefore, the simplest definition of a stem cell would be a cell with the capacity for self-maintenance. A more stringent (but still simplistic) definition of a 5 stem cell is provided by Potten and Loeffler (Development, 110:1001, 1990) who have defined stem cells as "undifferentiated cells capable of a) proliferation, b) self-maintenance, c) the production of a large number of differentiated functional progeny, d) regenerating the tissue after injury and e) a flexibility in the use of these options."

CNS disorders encompass numerous afflictions such as neurodegenerative diseases 10 (e.g. Alzheimer's and Parkinson's), acute brain injury (e.g. stroke, head injury, cerebral palsy) and a large number of CNS dysfunctions (e.g. depression, epilepsy, and schizophrenia). Degeneration in a brain region known as the basal ganglia can lead to diseases with various cognitive and motor symptoms, depending on the exact location. The basal ganglia consists of many separate regions, including the striatum (which consists of the caudate and putamen), 15 the globus pallidus, the substantia nigra, substantia innominate, ventral pallidum, nucleus basalis of Meynert, ventral tegmental area and the subthalamic nucleus. Many motor deficits are a result of neuronal degeneration in the basal ganglia. Huntington's Chorea is associated with the degeneration of neurons in the striatum, which leads to involuntary jerking movements in the host. Degeneration of a small region called the subthalamic nucleus is 20 associated with violent flinging movements of the extremities in a condition called ballismus, while degeneration in the putamen and globus pallidus is associated with a condition of slow writhing movements or athetosis. Other forms of neurological impairment can occur as a result of neural degeneration, such as cerebral palsy, or as a result of CNS trauma, such as stroke and epilepsy.

25 Another example is Parkinson's disease which is a chronic neurodegenerative disease particularly affecting the neurons of the substantia nigra pars compacta and its nigrostriatal projections. Although Parkinson's disease is considered a multisystem disease, it is mainly a movement disorder caused by a continuous, long lasting degeneration of the dopaminergic neurons that are located in the mesencephalic substantia nigra pars compacta.

30 Parkinson's disease (PD) is characterized by tremors, hypokinesia, rigidity and abnormal posture as the principal visible symptoms. The tremors in PD are of the resting type, since they occur when the muscles are in a state of relaxation. Its main pathological feature is the degeneration of dopaminergic neurons which have their cell bodies in the substantia nigra and their terminals projecting into the neostriatum. Dopamine is thus

significantly depleted in the neostriatum of PD patients. Changes to the substantia nigra and the neostriatal complex are linked to the tremors seen in PD. Compounds that damage the nigrostriatal dopaminergic system and cause hypokinesia, rigidity and tremors have the potential to be used as models for studying PD. Chemical agents such as 1-methyl-4-phenyl-
5 1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) damage the nigrostriatal dopaminergic neurons and are widely used to induce symptoms of PD. The effectiveness of these compounds rely on their ability to cause significant damage to the nigrostriatal dopaminergic system. The levels of symptoms are apparently dependent on the degree of nigrostriatal damage, which is somewhat difficult to control. As a result, the
10 symptoms produced by these agents are predominantly rigidity, hypokinesia and movements are not always consistent. Tremor, the most conspicuous symptom of PD is not a characteristic feature of the MPTP and 6-OHDA models.

Levodopa has been historically the medication of choice in treating Parkinson's disease. However, the currently available levodopa preparations are effective only for a
15 relatively short period and may even be deleterious under certain conditions. Administration of levodopa is especially successful during early stages of the disease. Adverse effects of levodopa, such as dyskinesias and hallucinations that occur at early stages of the disease are dose-dependent. These adverse effects are attributed to hypersensitivity of denervated striatal dopaminergic receptors to exogenous dopamine. At late stages of the disease additional types
20 of adverse effects appear as the response to levodopa becomes unpredictable, fluctuant and the duration of the response is reduced.

In order to cure Parkinson's disease, either a grafting procedure of neural tissues to restore dopamine innervation of the stratum or a pharmacological intervention that prevents neural degeneration and triggers renewal of nigral cells must be developed. Recently,
25 transplantation of embryonic dopaminergic neurons have been applied with varying degrees of success (Piccini et al., *Ann. Neurol.* 48:689-695 (2000); Freed et al., *New Engl. J. Med.* 344:710-719 (2001)). However, while transplantation approaches represent an improvement over currently available treatments, they suffer from a number of significant drawbacks. For example, after transplantation some cell types fail to integrate with host tissue. Another
30 disadvantage is that immunological incompatibility between donor and host could result in the rejection of the implanted cells. There is also the potential that the transplanted cells can result in tumor formation or pass infectious agents from the donor tissue to the host. Another significant drawback of transplantation procedures is that due to the invasiveness of the

procedures, which carry the risks involved in any major neurosurgical operation, damage to healthy brain tissue could occur.

Various treatments with hormones (U.S. Patent No. 5,116,873) and mitogens (U.S. Patent No. 6,165,783) have been also suggested for restoring the striatal dopamine levels by 5 replenishment of dopamine cells. However, none of the curative treatments have reached the market for larger populations of patients.

Thus, there is a need for improved therapies to treat neurodegenerative diseases. It is also necessary to find therapies for enhancing, improving, repairing, restoring and/or protecting the central nervous system function in a mammal, particularly a human at risk for, 10 or suffering from, a CNS disorder or dysfunction associated with damaged CNS cells. Therefore, this invention fulfills a need in the art for a method for treating central nervous system disease which involves replacing cells lost to the disease.

SUMMARY OF THE INVENTION

15 This invention relates generally to methods of influencing central nervous system cells to produce progeny that can replace damaged or missing neurons.

In one aspect, this invention provides a method of alleviating a symptom of a diseases or disorders of the nervous system comprising administering PDGF, VEGF or a combination thereof to modulate neural stem cell or neural progenitor cell activity *in vivo* to a patient 20 suffering from the diseases or disorders of the nervous system. In one embodiment, the PDGF, VEGF or combination thereof is administered in an amount of 0.001 ng/kg/day to 10 mg/kg/day. In another embodiment, the PDGF, VEGF or combination thereof is preferably administered in an amount of 0.01 ng/kg/day to 5 mg/kg/day. In a further embodiment, the PDGF, VEGF or combination thereof is more preferably administered in an amount of 0.1 25 ng/kg/day to 1 mg/kg/day. In another embodiment, the PDGF, VEGF or combination thereof is most preferably administered in an amount of 0.1 ng/kg/day to 1 μ g/kg/day. In one embodiment, a highest dose is given over the time span of 6-24 hours is better than a lower dose given during 1-2 weeks. In another embodiment, the highest dose may also be repeated intermittently. Preferred dosages have been described but would also include the following: 30 PDGF (MPTP study); 2.4 microgram/kg/day (mouse) for 3 days; PDGF (6OHDA stduy); 0.12 microgram/kg/day (rat) for 12 days (approx weight); PDGF (healthy animals) 0.12 microgram/kg/day (rat) for 7 days (approx weight).

Furthermore, it is highly likely that the intraparenchymal dose to achieve effect is less than the intracerebroventricular dose as the latter is a compartment with a considerably higher wash-out rate.

In one embodiment, the PDGF, VEGF or a combination thereof is administered by injection. Injection can be given subcutaneously, intraperitoneally, intramuscularly, intracerebroventricularly, intraparenchymally, intrathecally or intracranially.

Intraparenchymally refers to the parenchyma of the brain. The PDGF, VEGF or a combination thereof can also be administered to the buccal, nasal or rectal mucosa. In one embodiment, the PDGF, VEGF, or combination thereof is administered via peptide fusion or 10 micelle delivery.

In one embodiment, the diseases or disorders of the nervous system is selected from the group consisting of neurodegenerative disorders, neural stem cell disorders, neural progenitor disorders, ischemic disorders, neurological traumas, affective disorders, neuropsychiatric disorders and learning and memory disorders. In a preferred embodiment, the diseases or 15 disorders of the nervous system could be Parkinson's disease and Parkinsonian disorders, Huntington's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis, spinal ischemia, ischemic stroke, spinal cord injury and cancer-related brain/spinal cord injury. In another embodiment, the disease or disorder of the nervous system could be schizophrenia and other psychoses, depression, bipolar depression/disorder, anxiety syndromes/disorders, phobias, 20 stress and related syndromes, cognitive function disorders, aggression, drug and alcohol abuse, obsessive compulsive behaviour syndromes, seasonal mood disorder, borderline personality disorder, Cerebral palsy, life style (smart) drug, multi-infarct dementia, Lewy body dementia, age related/geriatric dementia, epilepsy and injury related to epilepsy, spinal cord injury, brain injury, trauma related brain/spinal cord injury, anti-cancer treatment related 25 brain/spinal cord tissue injury (radiation and cytostatics), infection and inflammation related brain/spinal cord injury, environmental toxin related brain/spinal cord injury, multiple sclerosis, autism, attention deficit disorders, nacrolepsy and sleep disorders.

In one embodiment, the VEGF is selected from the group consisting of VEGF-A, VEGF-B, VEGF-C and VEGF-D and the activity is proliferation or survival. The VEGF-A could be 30 VEGF-A₁₆₅ or VEGF-A₁₂₁. In another embodiment, the PDGF is selected from the group consisting of PDGF-B, PDGF-BB, PDGF-AB, PDGF-C, PDGF-D, PDGF-CC, PDGF-DD, PDGF-BC, PDGF-AC, PDGF-AD and PDGF-BD and the activity is proliferation, differentiation or survival. In another embodiment, the PDGF is PDGF-A or PDGF-AA and the activity is differentiation or survival. In a further embodiment, the PDGF, VEGF or

combination thereof could be a dimer consisting of two subunits, wherein each subunit is selected from the group consisting of PDGF A, PDGF B, PDGF C, PDGF D, VEGF A, VEGF B, VEGF C and VEGF D. In a preferred combination for use in the methods of the invention is a dimer. The dimer may be any homodimers or heterodimer with the following

5 members: PDGFA, PDGFB, PDGFC, PDGFD, VEGFA, VEGFB, VEGFC or VEGFD.

Since there is a total of eight possibility for the first member of the dimer and eight possibilities for the second member of the dimer, a total of 64 (8X8) combinations is possible and contemplated (e.g., PDGF AA, PDGF AB, VEGF AA, VEGF AB, PDGFA/VEGFB etc.).

10 In another aspect, the invention includes a method of modulating a PDGF receptor, VEGF receptor, or a combination thereof, on a neural stem cell or neural progenitor cell, the method comprising exposing the cell expressing the receptor to exogenous reagent, antibody, or affibody, wherein the exposure induces the neural stem cell or neural progenitor cell to proliferate or differentiate. In one embodiment, the VEGF receptor is Flt-1, Flk-1 or Flt-4. In
15 another embodiment, the PDGF receptor is PDGF- α receptor or PDGF- β receptor. The reagent is selected from the group consisting of VEGF-A, VEGF-B, VEGF-C, VEGF-D, PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, PDGF-DD, PDGF-BC, PDGF-AC, PDGF-AD and PDGF-BD. The antibody could be a monoclonal or a polyclonal antibody. In one embodiment, the neural stem cell or neural progenitor cell is derived from fetal brain, adult
20 brain, neural cell culture or a neurosphere. In another embodiment, the neural stem cell or neural progenitor cell is derived from tissue enclosed by dura mater, peripheral nerves or ganglia.

In a further aspect, the invention provides a method of drug screening and/or drug discovery using a non-human mammal, the method comprising: (a) administering a PDGF or
25 VEGF agonist to the non-human mammal; and (b) comparing the effect of administration of the PDGF or VEGF agonist in the mammal of step (a) with a referenced non-human mammal not administered the PDGF or VEGF agonist. In one embodiment, the agonist is selected from the group consisting of a peptide, small molecule, soluble receptor and receptor agonist wherein the exposure induces a neural stem cell or neural progenitor cell to proliferate or
30 differentiate. In one embodiment, the soluble receptor is a VEGF receptor, PDGF receptor or a combination thereof. In another embodiment, the VEGF receptor is selected from the group consisting of Flt-1, Flk-1 and Flt-4. In a further embodiment, the PDGF receptor is a PDGF- α receptor, a PDGF- β receptor or a combination thereof.

In another aspect, the invention includes a method for reducing a symptom of a central nervous system disorder in a mammal in need of such treatment comprising administering PDGF, VEGF or a PDGF or VEGF agonist to the mammal. In another aspect, the method further comprises administering a ventricle wall permeability enhancer. In one embodiment, 5 the ventricle wall permeability enhancer is administered before, during or after administration of PDGF, VEGF or a PDGF or VEGF agonist. In another aspect, the ventricle wall permeability enhancer or the PDGF, VEGF or PDGF or VEGF agonist are admixed with a pharmaceutically acceptable carrier. In a further embodiment, the method, further comprises administration of one or more agents selected from the group consisting of stem cell 10 mitogens, survival factors, glial-lineage preventing agents, anti-apoptotic agents, anti-stress medications, neuroprotectants, anti-pyrogenics and a combination thereof.

In one aspect, the invention provides a method for inducing the *in situ* proliferation or differentiation of a neural stem cell or neural progenitor cell located in the neural tissue of a mammal, the method comprising administering a therapeutically effective amount of PDGF 15 or VEGF to the neural tissue to induce the proliferation or differentiation of the cell. In one embodiment, the administration is systemic or local. In another embodiment, the administration of the PDGF, VEGF or PDGF or VEGF agonist alleviates a symptom of a diseases or disorders of the nervous system.

In a further aspect, the invention includes a method for accelerating the growth of neural 20 stem cells or neural progenitor cells in a desired target tissue in a subject, comprising administering intramuscularly to the subject an expression vector containing a PDGF or VEGF gene in a therapeutically effective amount. In one embodiment, the expression vector is a non-viral expression vector encapsulated in a liposome.

In another aspect, the invention provides a method of enhancing neurogenesis in a patient 25 suffering from a disease or disorder of the central nervous system, by intraventricular infusion of PDGF, VEGF or PDGF or VEGF receptor agonist.

In another aspect, the invention includes a method of increasing the number of dopaminergic neurons in a patient suffering from Parkinson's disease comprising the steps of: 30 (a) infusing the patient with PDGF to a lateral ventricle of the brain; (b) monitoring the patient to determine if there is proliferation and differentiation of NSCs and NPCs; and (c) repeating step (a) until the desired effect is achieved.

In one aspect, the invention provides a method for producing a population of cells enriched for human neural stem cells or human neural progenitor cells which can initiate neurospheres, comprising: (a) contacting a population containing neural stem cells or neural

progenitor cells with a reagent that recognizes a determinant on a VEGF or PDGF receptor; and (b) selecting for cells in which there is contact between the reagent and the determinant on the surface of the cells of step (a), to produce a population highly enriched for central nervous system stem cells. In one embodiment, the reagent is a reagent selected from the 5 group consisting of a soluble receptor, a small molecule, a peptide, an antibody and an affibody. In another embodiment, the population containing neural stem cells or neural progenitor cells is obtained from any population of cells which gives rise to neural tissue. The neural tissue could fetal brain or adult brain.

In another aspect, the invention includes a method of activating a VEGF or PDGF 10 receptor on a neural stem cell or neural progenitor cell, the method comprising exposing a neural stem cell or neural progenitor cell expressing a receptor to exogenous reagent, antibody, or affibody, wherein the exposure induces the neural stem cell or neural progenitor cell to proliferate or differentiate. In one embodiment, the neural stem cell or neural progenitor cell is derived from fetal brain, adult brain, neural cell culture or a neurosphere.

15 In a further aspect, the invention provides an *in vitro* cell culture comprising a cell population enriched in receptor expressing cells wherein the receptors are selected from the group consisting of Flt-1, Flk-1, Flt-4, PDGF- α and PDGF- β receptor.

In another aspect, the invention provides a method for treating diseases or disorders of the 20 central nervous system comprising administering the population of neural stem cells or neural progenitor cells described in a previous aspect of the invention to a mammal in need thereof.

In one aspect, the invention includes a non-human mammal engrafted with the human neural stem cells or neural progenitor cells described in a previous aspect of the invention. In one embodiment, the non-human mammal is selected from the group consisting of a rat, mouse, rabbit, horse, sheep, pig and guinea pig.

25 In a further aspect, the invention provides a method of reducing a symptom of a disease or disorder of the central nervous system in a subject comprising the steps of administering into the spinal cord of the subject a composition comprising a population of isolated primary neurons obtained from a fetus; and PDGF, VEGF, a PDGF or VEGF agonist or a combination thereof such that the symptom is reduced.

30 In another aspect, the invention includes a host cell transformed or transfected with a molecule selected from the group consisting of SEQ ID NOs: 1, 2, 3 and 4. In one embodiment, the host cell is a eukaryotic cell or a prokaryotic cell. In another embodiment, the host cell is selected from the group consisting of a mammalian cell, a bacterial cell, a

yeast. In a further embodiment, FuGENE 6 transfection reagent (Roche Diagnostics) is used to transfect the host cell.

In one embodiment, the invention includes a method of gene delivery and expression in a target cell of a mammal, comprising the step of introducing a viral vector into the target cell, 5 wherein the viral vector has at least one insertion site containing a nucleic acid selected from the group consisting of SEQ ID NOS: 1, 2, 3 and 4, the nucleic acid gene operably linked to a promoter capable of expression in the host. In one embodiment, the viral vector is a non-lytic viral vector.

In a further embodiment, the invention includes a method of gene delivery and expression 10 in a target cell of a mammal comprising the steps of: (a) providing an isolated nucleic acid fragment of sequence selected from the group consisting of SEQ ID NOS:1, 2, 3 and 4; (c) selecting a viral vector with at least one insertion site for insertion of the isolated nucleic acid fragment operably linked to a promoter capable of expression in the target cells; (d) inserting the isolated nucleic acid fragment into the insertion site, and (e) introducing the vector into 15 the target cell wherein the gene is expressed at detectable levels. In one embodiment, the virus is selected from the group consisting of retrovirus, adenovirus, and pox virus. In another embodiment, the pox virus is vaccinia. In a preferred embodiment, the virus is selected from the group consisting of retrovirus, adenovirus, iridoviruses, coronaviruses, togaviruses, caliciviruses and picornaviruses. In another embodiment, the virus is a strain 20 that has been genetically modified or selected to be non-virulent in a host.

In another aspect, the invention includes a method for alleviating a symptom of a disease or disorder of the central nervous system in a patient comprising the steps of: (a) providing a population of neural stem cells or neural progenitor cells; (b) suspending the neural stem cells or neural progenitor cells in a solution comprising a mixture comprising a growth factor dimer 25 wherein each half of the dimer is selected from the group consisting of PDGF A, PDGF B, PDGF C, PDGF D, VGEF A, VGEF B, VGEF C, and VGEF D, to generate a cell suspension; (c) delivering the cell suspension to an injection site in the central nervous system of the patient to alleviate the symptom. In one embodiment, the method further comprises the step of injecting the injection site with the growth factor for a period of time 30 before the step of delivering the cell suspension. In another embodiment, the method further comprises the step of injecting the injection site with said growth factor after said delivering step.

Additional aspects, features, embodiments and advantages of the invention will be set forth, in the description that follows, or may be learned from practicing or using the invention. The objects and advantages may be realized and attained by means of the features and combinations particularly pointed out throughout this description and the appended 5 claims. It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not to be viewed as being restrictive of the invention as claimed.

BRIEF DESCRIPTION OF THE DRAWINGS

10

FIG. 1 depicts the effect of PDGFs on proliferation of cultured, non-adherent mouse neurospheres.

15

FIG. 2 shows the effect of PDGFs on proliferation of adherent cultured mouse NSC/progenitor cells.

FIG 3 is Western blots showing the effect of PDGF-AA in cultured neurospheres. Downregulation of GFAP (left); upregulation of β -III Tubulin (right).

20

FIG 4 depicts the effect of PDGF-AA in cultured mouse NCCs/neural progenitor cells (NPCs). Upper panel: adult mouse NSCs treated with PDGF-AA for 6 days switch from an undifferentiated (left panel) to a neuronal phenotype (right panel) increasing the specific neuronal marker β -III Tubulin. Lower panel: in contrast to the above, adult mouse NSCs treated with PDGF-AA for 6 days significantly decrease the specific expression of the glial 25 specific marker GFAP indicating that the astroglial component was reduced in presence of PDGF-AA.

30

FIG. 5 shows the effect of PDGF-AA and PDGF-BB on neuronal differentiation of adult mouse stem cells. Compared to the control (panel A) the stimulation with PDGF-AA (panel B) and PDGF-BB (panel C) significantly increase the number of β -III Tubulin positive cells in culture.

FIG. 6 is a Western blot showing the effect of PDGF-AA and PDGF-BB on neuronal differentiation of adult mouse stem cells. Compared with the control (A) the stimulation with PDGF-AA (B) and PDGF-BB (C) significantly increased levels of β -III Tubulin protein.

5 Sample loads were normalized.

FIG. 7 represents the effect of PDGF-BB on the number of BrdU positive cells in the dentate gyrus.

10 FIG. 8 shows the effect of PDGF-BB on BrdU positive cells in the striatum.

FIG. 9 depicts a large neuron in the MPTP-lesioned mouse receiving PDGF. This tyrosine hydroxylase-positive (brown) nerve cell with a violet nucleolus in the centrally placed nucleus without brown staining had an estimated volume of $10,900 \mu\text{m}^3$. Anti-tyrosine hydroxylase was visualized with the avidin-biotin-peroxidase-DAB method and cresyl violet was employed as counterstain. Bar = $10\mu\text{m}$.

15 FIG. 10 represents a small tyrosine hydroxylase-positive neuron in the MPTP-lesioned PDGF-treated mouse. The cell had an estimated volume of $170 \mu\text{m}^3$, e.g. similar to a small glia cell, but demonstrated a clear neuronal bipolar phenotype with long dendrites that extended for more than $100\mu\text{m}$ in the $40 \mu\text{m}$ thick section.

20 FIG. 11 shows a ^3H thymidine label (black dots) over a substantia nigra neuron (Nissl stain) in a PDGF-treated MPTP-lesioned mouse. Bar = $10 \mu\text{m}$.

25 FIG. 12 shows that PDGFR-A and PDGFR-B genes are expressed in cultured human neural stem cells.

30 FIG. 13 shows immunohistochemically stained BrdU-labeled cells in the striatum at 5 weeks after PDGF infusion. (A) PBS control, (B) PDGF treated.

FIG. 14 represents the number of BrdU-labeled cells in the striatum at 12 days and 5 weeks after PDGF or BDNF infusion. * $p < 0.05$ compared to PBS infused controls. Means \pm SEM.

FIG. 15 depicts the number of BrdU/NeuN double-labelled cells in the striatum at 5 weeks after PDGF or BDNF infusion. Note that due to heterogeneity of variance with groups, data were logarithmically transformed. *p < 0.05 compared to PBS infused controls. Means \pm SEM.

5

FIG. 16 shows the number of BrdU-labeled cells in the substantia nigra at 12 days and 5 weeks after PDGF or BDNF infusion. *p < 0.05 compared to PBS infused controls. Means \pm SEM.

10

FIG. 17 depicts neurogenesis in the hippocampus which is characterized by proliferative clusters of cells along the border between the granule cell layer (g) and the hilus region (h). These cells begin to migrate into the granule cell layer about 1 week after their last cell division and can be colabeled with markers for granule cells (e.g., NeuN and Calbindin).

15

FIG. 18 represents Flk-1-positive cells in the dentate gyrus. Frequently Flk-1 positive cells are associated with clusters of proliferating cells. These clusters contain endothelial cells as well as NSCs/NPCs. (A) Multiple immunofluorescence with BrdU, VEGF and Flk-1. Note the colocalization of Flk-1 and BrdU. (B) BrdU positive cells are associated with blood vessels as shown with RECA staining (rat endothelial cell antigen).

20

FIG. 19 shows the localization of Flk-1 immunoreactive cells in the ventricle wall. The ependymal layer of the ventricle wall shows intense immunoreactivity for Flk-1. Since neural stem cells can be generated from ependymal cells of the ventricle wall, Flk-1 could function as a stem cell marker and has perhaps a function in stem cell recruitment.

25

FIG. 20 represents intracerebroventricular infusion of VEGF. VEGF was infused via osmotic minipumps for 7 days into the lateral ventricle of adult rats. Increased BrdU labeling in the granule cell layer of the dentate gyrus is observed 4 weeks after infusion of VEGF into the lateral ventricle.

30

FIG. 21 shows VEGF mRNA levels. Neurospheres were cultured in a defined medium in the presence of EGF and FGF. Using RT-PCR, the mRNA from these cells was examined for the

expression of 4 different isoforms of VEGF. GADPH expression served as quality control of the mRNA.

FIG. 22 shows Flk-1 mRNA levels. *Left.* Neural stem cells from the lateral ventricle wall (LV) and hippocampus (HC) of the adult rodent can be grown as neurospheres using defined medium and the growth factors FGF-2 and EGF. *Right.* From spheres under growth condition mRNA was isolated and RT-PCT for Flk-1 was performed. Actin was used as a control for mRNA amount.

FIG. 23 shows the release of VEGF protein. Competitive ELISA for quantification of VEGF-secretion was used on adult NSCs from the rat lateral ventricle wall. As a positive control, the endothelial cell line HMEC-1 and primary retinal pigment epithelial cells (RPE) were used.

FIG. 24 depicts VEGF-dependent proliferation of NSCs. Neurosphere cultures were grown in serum free medium containing EGF/FGF-2. VEGF was added to this medium in different concentrations for 7 days and the total number of NSCs was counted.

FIG. 25 shows that the effect of VEGF is modulated via the Flk-1 receptor. NSC cultures were stimulated for 7 days with different concentrations of VEGF-A₁₆₅ (triangle) and VEGF-A₁₂₁ (squares). VEGF-A₁₆₅ bind to all VEGF-receptors whereas VEGF-A₁₂₁ binds preferentially to the Flk-1 receptor.

FIG. 26 shows the lineage potential of clonally-derived rat neural stem cell cultures. Individual clones derived from rat lateral ventricle wall cultured on poly-ornithin/laminin matrix were differentiated in NB/B27 medium supplemented with 1%FCS for 7 days and immunostained for the presence of (a) neurons with β III-tubulin, (b) astrocytes with GFAP or (c) oligodendrocytes with GalC (bar = 40 μ m).

FIG. 27 is a Dose-Response-Curve for VEGF in rat neural stem cells from the adult lateral ventricle wall. The dose-response curve was performed on clonally derived neural stem cells. Maximal growth activity can be observed starting at 50 ng/ml.

FIG. 28 (A) In basal medium VEGF (50ng/ml) stimulates the expansion of neural stem cell cultures about 5-fold. The VEGF-Receptor inhibitors PADQ and SU1498 are both able to block the VEGF response at concentrations specific for VEGF receptor flk-1. Total cell counts at 7 days after treatment. (B) In growth conditions (including EGF and FGF-2), VEGF 5 stimulates the expansion of neural stem cell cultures about 2-fold. The VEGF-Receptor tyrosine kinase inhibitors PADQ and SU1498 are both able to block the VEGF response. Total cell counts at 7 days after treatment in growth medium .

FIG. 29 shows VEGF production and release into the cell culture medium. Cells were 10 cultured in serum free medium and medium was collected at 2 days (2d) or 8 days (8d) in medium. HUVEC: Human umbilical vein endothelial cells, huRPE: human retinal pigment epithelial cells.

FIG. 30 represents NSCs under growth conditions (with EGF and FGF-2) VEGF-receptor- 15 Tyrosine kinase receptor blocker PADQ and SU1498 are both able to significantly reduce the growth of neural stem cell cultures. DMSO was used to dissolve the inhibitors and had no effect on the growth rate. Total cell counts at 7 days after treatment.

FIG. 31 shows that BrdU incorporation is increased under VEGF and reduced under VEGF 20 receptor blockade. Neural stem cell cultures were treated with 50ng/ml VEGF, 100nM PADQ or 700nM SU1498 for 7 days. BrdU (10 μ M) was added to the culture medium 24 hrs before cells were harvested and lysed. DNA was extracted and BrdU content was determined using an anti-BrdU-ELISA. The data are presented as percent changes in optical density compared to control (Growth medium).

25 FIG. 32 shows that DNA fragmentation is increased under VEGF and reduced under VEGF receptor blockade. Neural stem cell cultures were treated with 50ng/ml VEGF, 100nM PADQ or 700nM SU1498 for 7 days. BrdU (10 μ M) was added to the culture medium 24 hrs before cells were harvested and lysed. DNA was extracted and BrdU content was determined using 30 an anti-BrdU-ELISA. The data are presented as percent changes in optical density compared to control (Growth medium).

FIG. 33 represents *in vitro* generation of spheres is stimulated by intraventricular VEGF infusion. After 7 days of intraventricular infusion of either artificial cerebrospinal fluid (CSF)

or VEGF, cells were isolated from the lateral ventricle wall, seeded at 10000 cells/well in Growth medium (Neurobasal + B27 + EGF + FGF-2 + heparin) and grown in culture for 3 weeks. The efficiency to generate spheres from the lateral ventricle wall is substantially increased by previous *in vivo* infusion of VEGF. It was concluded from this finding, that
5 VEGF stimulates the multipotent neural stem cells of the lateral ventricle wall *in vivo* leading to a facilitated neural stem cell growth *in vitro*.

FIG. 34 shows that the VEGF and FLT-4 genes are expressed in cultured human neural stem cells.

10

FIG. 35 shows that the FLT-1 and FLK-1 genes are expressed in cultured human neural stem cells.

15

DETAILED DESCRIPTION OF THE INVENTION

It has been discovered that certain reagents are capable of modulating the differentiation, migration, proliferation and survival of neural stem/progenitor cells both *in vitro* and *in vivo*. As used herein, the term “modulate” refers to having an affect in such a way as to alter the differentiation, migration, proliferation and survival of neural stem cell 20 (NSC) or neural progenitor cell (NPC) activity. Since undifferentiated, pluripotent stem cells can proliferate in culture for a year or more, the invention described in this disclosure provides an almost limitless supply of neural precursors.

As used herein, the term “neural stem cells” (NSCs) can be identified by their ability to undergo continuous cellular proliferation, to regenerate exact copies of themselves (self-renew), to generate a large number of regional cellular progeny, and to elaborate new cells in 25 response to injury or disease. The terms “neural progenitor cells” or “neural precursor cells” (NPCs) mean cells that can generate progeny that are either neuronal cells (such as neuronal precursors or mature neurons) or glial cells (such as glial precursors, mature astrocytes, or mature oligodendrocytes). Typically, the cells express some of the phenotypic markers that 30 are characteristic of the neural lineage. Typically, they do not produce progeny of other embryonic germ layers when cultured by themselves *in vitro* unless dedifferentiated or reprogrammed in some fashion.

As used herein, the term “reagent” refers to any substance that is chemically and biologically capable of activating a receptor, including peptides, small molecules, antibodies

(or fragments thereof), affibodies and any molecule that dimerizes or multimerizes the receptors or replaces the need for activation of the extracellular domains. In one embodiment, the reagent is a small molecule.

As used herein, the term "antibody" as used in this disclosure refers to both 5 polyclonal and monoclonal antibody. The ambit of the term deliberately encompasses not only intact immunoglobulin molecules, but also such fragments and derivatives of immunoglobulin molecules (such as single chain Fv constructs, diabodies and fusion constructs) as may be prepared by techniques known in the art, and retaining a desired antibody binding specificity. The term "affibody" (U.S. Patent No. 5,831,012) refers to 10 highly specific affinity proteins that can be designed to bind to any desired target molecule. These antibody mimics can be manufactured to have the desired properties (specificity and affinity), while also being highly robust to withstand a broad range of analytical conditions, including pH and elevated temperature. The specific binding properties that can be engineered into each capture protein allow it to have very high specificity and the desired 15 affinity for a corresponding target protein. A specific target protein will thus bind only to its corresponding capture protein. The small size (only 58 amino acids), high solubility, ease of further engineering into multifunctional constructs, excellent folding and absence of cysteines, as well as a stable scaffold that can be produced in large quantities using low cost bacterial expression systems, make affibodies superior capture molecules to antibodies or 20 antibody fragments, such as Fab or single chain Fv (scFv) fragments, in a variety of Life Science applications.

Preferred reagents of the invention include members of the Vascular Endothelial Growth Factor (VEGF) family and members of the Platelet Derived Growth Factor (PDGF) family. In one embodiment, the reagent may be VEGF-A, VEGF-B, VEGF-C, VEGF-D, 25 PDGF-A, PDGF-B, PDGF-BB, PDGF-AA or PDGF-AB.

The invention provides a method for *in vivo* modulation of PDGF and VEGF activity and for therapeutic administration of PDGF and VEGF and drug screening. In one embodiment, PDGF, VEGF or their agonist are administered to neural tissue. In a preferred embodiment, the neural tissue is fetal or adult brain. In yet another embodiment, the 30 population containing neural or neural-derived cells is obtained from a neural cell culture or neurosphere.

Receptors for the invention include members of the VEGF receptors and members of the PDGF receptors. Such receptors may include: Flt-1, Flk-1, Flt-4, PDGF- α , PDGF- β and VEGF receptor.

PDGF Receptors and Their Ligands

PDGF, an autocrine cytokine, is involved in the development of the CNS as well as in the maintenance of the adult CNS. The mechanisms triggered by PDGF include differentiation and survival of dopaminergic neurons. *In vitro*, PDGF was shown to support differentiation and to influence multipotent stem cells towards a neuronal fate. Johe et al., 1996, *Genes Dev* 10, 3129-3140; Williams et al., 1997, *Neuron* 18, 553-562.

PDGF is also a potent mitogen for mesenchymal, glial, and capillary endothelial cells. As such, it acts as a strong chemoattractant for fibroblasts and smooth muscle cells, as well as monocytes and neutrophils. The mitogenic activity of the localized PDGF results in proliferation of these cells at the site of injury, contributing to the process of wound repair.

Purified native PDGF, a glycoprotein of about 30,000 daltons, is composed of two disulfide-linked polypeptide chains. Two forms of these chains, designated A and B, have been identified. The native protein occurs as the homodimer AA or BB or the heterodimer AB, or a mixture thereof. A partial amino acid sequence for the PDGF-A chain has been identified (Johnsson et al. (1984) *EMBO J.* 3:921-928) and cDNAs encoding two forms of PDGF A-chain precursors have been described (U.S. Pat. No. 5,219,759). The mature A-chain consists of a 104 amino acid polypeptide that is derived by proteolytic processing of a 211 amino acid precursor polypeptide. The cDNA encoding the PDGF-B chain has also been described (Nature (1985) 316:748-750). The mature B-chain consists of a 109 amino acid polypeptide that is derived by proteolytic processing of a 241 amino acid precursor polypeptide. The mature A and B chains of PDGF show sequence identity of 51%, with the eight cysteine residues being conserved in each of the chains (Johnsson et al. (1984) *EMBO J.* 3:921-928).

The three isoforms of PDGF, PDGF-AA, PDGF-AB, and PDGF-BB, interact differentially with structurally related receptors designated PDGF α and β receptors. Each of these receptors has an extracellular region featuring five immunoglobulin-like domains, a lipophilic transmembrane domain and an intracellular part with a tyrosine kinase domain containing a characteristic insert amino acid sequence. The tyrosine kinase activity of these receptors is essential for transmission of the mitogenic signal into the cell.

The three dimeric forms of PDGF exhibit different binding affinities for the two known PDGF receptor gene products, α and β . The β receptor recognizes the PDGF B chain and is dimerized in the presence of PDGF-BB. The α receptor recognizes the PDGF B and A chains and can be dimerized by PDGF-BB, PDGF-AA, and PDGF-AB (see, for example,

Abboud et al (1994) *J. Cell. Phys.* 158:140-150). The amino acid residue region of PDGF-BB which is involved in binding or activation of the receptor has been narrowed down to residues Ile²⁵-Phe³⁷ (Giese et al. (1990) *Mol. Cell. Biol.* 10:5496-5501).

Most recently, an additional member of the PDGF/VEGF family of growth factors 5 was identified, which is called PDGF-C. PDGF-C has a two-domain structure not previously recognized within this family of growth factors, an N-terminal Clr/Clv/embryonic sea urchin protein Uegf/bone morphogenetic protein 1 (CUB) domain, and a C-terminal PDGF/VEGF homology domain (P/VHD). The structure of the P/VHD in PDGF-C shows a low overall sequence identity with other PDGF/VEGF homology domains, although the eight invariant 10 cysteine residues involved in inter- and intra-molecular disulfide bond formation are present. The cysteine spacing in the central, most conserved region of this domain is different from other PDGF/VEGF domains, with an insertion of three amino acid residues. Despite the fact that the insertion occurs close to the loop 2 region which has been proposed to be involved in receptor binding, it was shown that this domain of PDGF-CC dimers binds PDGFR-alpha 15 with an affinity almost identical to homodimers of PDGF-A or -B chains. In addition, four extra cysteine residues are present in this domain. Full length and truncated PDGF-CC dimers were found not to bind to VEGFR-1, -2 or -3, or to PDGFR-beta.

PDGF-C requires proteolytic removal of the N-terminal CUB domain for receptor 20 binding and activation of the receptor. This indicates that the CUB domains are likely to sterically block the receptor binding epitopes of the unprocessed dimer. The *in vitro* and *in vivo* proteolytically processed proteins are devoid of N-terminal portions corresponding to more than 14-16 kDa as determined from SDS-PAGE analysis that is consistent with a loss of the 110 amino acid long CUB domain and a variable length portion of the hinge region between the CUB and core domains.

25 PDGF-C is not proteolytically processed during secretion in transfected COS cells indicating that proteolytic removal of the CUB domain occurs extracellularly, and not during secretion. This is in contrast to PDGF-A and -B (Stman et al., *J. Cell. Biol.*, 1992 118 509-519) which appear to be processed intracellularly by furin-like endoproteases (Nakayama et al., *Biochem J.*, 1997 327 625-635).

30 *In situ* localization studies demonstrate expression of PDGF-C in certain epithelial structures, and PDGFR-alpha in adjacent mesenchyme, indicating the potential of paracrine signaling in the developing embryo. PDGF-C expression seems particularly abundant at sites of ongoing ductal morphogenesis, indicating a role of the factor in connective tissue remodeling at these sites. The expression pattern is distinct from that of PDGF-A or PDGF-B

indicating that the three growth factors have different roles despite their similar PDGFR-alpha binding and signaling activities. This is illustrated by the mouse embryonic kidney, in which PDGF-C is expressed in early aggregates of metanephric mesenchyme undergoing epithelial conversion, whereas PDGF-A is expressed in more mature tubular structures, and

5 PDGF-B by vascular endothelial cells. PDGFR-alpha is expressed in the mesenchyme of the kidney cortex, adjacent to the sites of PDGF-C expression, indicating that this mesenchyme may be targeted specifically by PDGF-C. Indeed, PDGFR-alpha-/-mouse embryos show an extensive loss of the cortical mesenchyme adjacent to sites of PDGF-C expression, not seen in PDGF-A-/-mice or in PDGF-A/B-/-mice, indicating that PDGF-C has an essential role in

10 the development of kidney mesenchyme. Northern blots show PDGF-C mRNA in a variety of human tissues, including heart, liver, kidney, pancreas and ovary.

Another protein in the PDGF family is PDGF-D. Structural predictions based on the PDGF-D sequence and its homology to other growth factors suggests that the polypeptide can form homomultimers or heteromultimers. PDGF-D heteromultimers may comprise a

15 polypeptide from another member of the PDGF/VEGF family of proteins, including VEGF, VEGF-B, VEGF-C, VEGF-D, PDGF-D /PDGF-C, PlGF (Maglione et al., Proc. Natl. Acad. Sci. USA 88:9267-9271, 1991), PDGF-A (Murray et al., U.S. Pat. No. 4,899,919; Heldin et al., U.S. Pat. No. 5,219,759), or PDGF-B (Chiu et al., Cell 37:123-129, 1984; Johnsson et al., EMBO J. 3:921-928, 1984).

20 The PDGF-D polypeptide chain comprises a growth factor domain, a CUB domain, and an interdomain linking the CUB and growth factor domains. The growth factor domain is characterized by an arrangement of cysteine residues and beta strands that is characteristic of the "cystine knot" structure of the PDGF family. The CUB domain shows sequence homology to CUB domains in the neuropilins (Takagi et al., Neuron 7:295-307, 1991; Soker et al., Cell 92:735-745, 1998), human bone morphogenetic protein-i (Wozney et al., Science 242:1528-1534, 1988), porcine seminal plasma protein and bovine acidic seminal fluid protein (Romero et al., Nat. Struct. Biol. 4:783-788, 1997), and *X. laevis* tolloid-like protein (Lin et al., Dev. Growth Differ. 39:43-51, 1997).

25 Binding of PDGF to its receptors initiates numerous biological responses including proliferation, chemotaxis, differentiation and survival. The signal transduction process involves receptor dimerization and activation of intrinsic receptor kinase activity which leads to receptor autophosphorylation at up to nine sites. Subsequently, depending on the cell context the signal relay cascade diverges to involve many different pathways, most of which end with an event regulating transcription (for refs see Valenzuela et al., 1997, Brain Res.

Rev 24, 77-89). Receptors for PDGF are expressed in structures relevant for the treatment of Parkinson's disease. See, Valenzuela et al., 1997, Brain Res. Rev 24, 77-89.

PDGF and its receptors participate in various physiological processes such as embryonal development and wound healing. An abnormally high activity of PDGF is believed to play a central role in the etiology of certain adverse pathophysiological situations, such as atherosclerosis and restenosis, as well as in other non-malignant diseases such as pulmonary fibrosis, glomerular nephritis, and rheumatoid arthritis. Moreover, the PDGF B-chain was acquired as the sis oncogene by the acutely transforming simian sarcoma virus. Expression of a PDGF-like growth factor in cells infected with simian sarcoma virus or transfected with the sis oncogene leads to their transformation due to the persistent autocrine stimulation of the resident PDGF receptors. Furthermore, certain human tumors possess PDGF receptors and express the genes for PDGF which suggest that autocrine growth stimulation via PDGF receptors contributes to the malignant phenotype of these tumors.

The nucleic acid sequences for human PDGF-A, PDGF-B, PDGF-C and PDGF-D are represented below:

PDGF-A (GenBank entry # NM_002607)

ACGCGCGCCCTGCGGAGCCGCCAACCTCCGGCAGGCCGGCCTGCGCCTACTCCTCCTCCTCTCCCGGGCGG
 20 CGGCTCGGGCGGAGGCCGACTCGGCCCTGCGCCGCCCTCAGGCCGCGCGGGCGCAGCGAGGGCGGAGCGCGGGCG
 CGGGGGTGGTGGCTGCCAGGCCGCTGGCCGGGGCGCTGCCGGCCGGCGAGGGGGTGTGGCCGGCGCTGCAAGAGGAGG
 CGGAGCCGAGGGCGCCGCCGGAGGGGGTGTGGCCGGCGAGGGCGCTCGCAGCTCGCAGCCGGGCCAGGGCGT
 25 CGGGAGGCAGGCCGGGGCGCGGTGGCCGGCGAGCTCCCTCCGGAGTTCTTGGGCTGATG
 CAGGCAGGTGATCGGTGTGGCGGGCGGCCGGCGGCCGGCGGCCAGACTCCCTCCGGAGTTCTTGGGCTGATG
 TCCGCAAATATGAGAATTACCGGCCGGTCGCTCCTGAAGCCAGCGCGGGAGCGAGCGCGGGCGGCCAGCA
 CGGGGAACGCACCGAGGAAGAAGCCCAGCCCCGCCCTCCGCCCCCTTCCGTCCCCACCCCTACCCGGCGGCCA
 GGAGGCTCCCCGGCTCGGGCGCGCAGCTCCCTGTTCTCCCTCCGGCTGCGCTGCCCTCCGACTCA
 30 CTGCTGCCGGGGCGCCGTCGCCAGCTCGTGTCCCGGCCACCCCTCCGGCCGCGCTCCCTAAGGGATG
 GTACTGAATTTCGCCGCCACAGGAGACCGGGCTGGAGCGCCGCCCGCCCTCGCCTCTCCGAGCAGCCAGC
 GCCTCGGGACGCGATGAGGACCTTGGCTTGCCTGCTCGCTCGGATACCTCGCCATGTTCTGGCGA
 GGAAGCCGAGATCCCCCGCGAGGTGATCGAGAGGCTGGCCCGAGTCAGATCCACAGCATCCGGACCTCCAGCG
 ACTCTGGAGATAGACTCCGTAGGGAGTGAGGATTCTTGGACACCAGCCTGAGAGCTCACGGGTCCACGCCAC
 35 TAAGCATGTGCCGAGAAGCGCCCGCCATTGGAGGAAGAGAAGCATCGAGGAAGCTGCTCCCGCTGTCTG
 CAAGACCAGGACGGTCATTACGAGATTCCCTCGGAGTCAGGTGACCCCACGTCCGCCAACCTCCGTG
 CCCGTGCGTGGAGGTGAAACGCTGCACCGGCTGCTGCAACACGAGCAGTGTCAAGTGCCAGCCCTCCCGCGTCCA
 CCACCCGAGCGTCAAGGTGCGCAAGGTGGAATACGTCAGGAAGAAGCCAAATTAAAAGAAGTCCAGGTGAGGTT
 AGAGGAGCATTGGAGTGCCCTGCGCACCACAAGCCTGAATCCGGATTATCGGAAGAGGACACGGGAAGGCC
 40 TAGGGAGTCAGGTAAAAACGGAAAAGAAAAGGTTAAACCCACCTAAGATGTGAGGTGAGGATGAGCCGCAGC
 CCTTCCCTGGGACATGGATGTACATGGCGTGTACATTCCCTGAACCTACTATGTACGGTGTCTTATTGCCAGTGT
 GCGGTCTTGTCTCCCTCGTAAAAACTGTGTCGAGAACACTCGGGAGAACAAAGAGACAGTCACATTGTT
 TAATGTGACATCAAAGCAAGTATTGTAGCACTCGGTGAAGCAGTAAGAAGCTTCTGTAAAAAGAGAGAGAGA
 GAGAGAGAGAGAGAAAACAAACCAAAATGACAAAAACAAACGGACTCACAAAATATCTAAACTCGATGAGA
 TGGAGGGTGCCTGGGATGGAAGTGCAGAGGTCTCAGCAGACTGGATTCTGTCCGGGTGGTACAGGTGCT
 45 TTTTGCCGAGGATGCAAGAGCCTGCTTGGGAACGACTCCAGAGGGTGTGCTGGTGGCTCTGCAGGGCCCGAGG
 AAGCAGGAATGTCTGGAAACCGCCACGCGAACTTTAGAAACCACACCTCCTCGCTGTAGTATTAAAGCCATAC
 AGAAACCTCCTGAGAGCCTTAAGTGGTTTTTTTTGTTTGTGTTTTTTTTTTTTTTTTTTTTTTTTTTTT
 TTTTTTTTTTTTACACCATAAGTGTATTAAAGCTCCTTTACTCTTGCTAGCTTTTTTTTTTTTTTTTT
 TTTTTTTTTTTTTAATTATCTTGGATGACATTACACCGATAACACACAGGCTGCTGTAAGTCAGGACA

GTGCGACGGTATTTCCTAGCAAGATGCAAACATAATGAGATGTATTAAAATACATGGTATACTACCTATGC
ATCATTCTAAATGTTCTGGCTTGTGTTCTCCCTTACCTGCTTATTGTTAAGCCATTGAA
GAACATGCGTCAACCAATCGTACGCCGTCCTGCGGACCTGCCCCAGAGCCGTTGGCTGAGTACA
ACTTGTTCCCGCAGTGCACACCTAGAATGCTGTGTTCCACGCCGACGTGAGATGCA
TTGCCGCTTCTGTCTGTGTTGTTGGTGTGCCCTGGTGCCTGGTGGCGGTCA
CTCCCTGCTGCCAGTGTGTTGGACAGAACCAAATTCTTA
TTTTGGTAAGATATTGTGCTTACCTGTATTAAACAGAAATGTGTGTGTTGTTGTTGAA
GTTTGTATGTTACCTAATATTACCTGTTGTATACCTGAGAGCCTGCTATGTTCTTGTGATCCAAA
TTAAAAAAAAAATACCAAC (SEQ ID NO:1)

10

PDGF-B (GenBank entry # NM_002608)

PDGF-C (GenBank entry # AF260738)

5 ggcacgaggattatgtggaaactaccctgcgattctctgctgccagagcaggctggcgcttccaccccaagtgc
 cccttccctggcggtggtaaaagagactcggagtcgctgcttccaaagtgcggccgtgaatgcgcacc
 10 ccagtcaagccaaatgagccttccggcttctcgtgacatctgcctggccggccagagacaggggactcag
 gcgaaatccaacccatgagtagtaaattccagttccagcaacaaggaaacagaacggactacaagatcctcag
 gagagaattattactgtgtctactaatggaaagtattcacagccaaagggttccctcataacttaccaagaatc
 15 gtcttggatggagatttagtgcgttagcagtagggaaaatgtatggatacaacttacgttgcgtatggaaat
 gaagaccaggagaatgacatatgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt
 20 ttatacagctgcacacccctgttaacttctcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
 25 ccaggtgtctccgtttaacgcgtgtggggactgtgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
 ttatacactcaccgacgtggccctggagcaccatgaggactgtgcgttgcgttgcgttgcgttgcgttgcgtt
 30 gacatcaaacagaatttaggatgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 35 gacatcaaacagaatttaggatgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 40 gacatcaaacagaatttaggatgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 45 gacatcaaacagaatttaggatgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 50 gacatcaaacagaatttaggatgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 55 gacatcaaacagaatttaggatgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt

(SEQ ID NO:3)

PDGF-D (GenBank entry # AF336376)

30 cgctcgaaaagttcagcatgcaggaagtggggagagactcgccgatttagcacagcgacccggggccagcgcagg
 cgagcgcaggcgccgagagcgcaggcgccgcgtcggtcccgaggcagaacccggcttttctggagcga
 35 cgctgtctctagtcgtatccaaatgcaccggctcatcttgcgttgcgttgcgttgcgttgcgttgcgttgc
 gagcaatcacccacagacttgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
 40 tagattcccaacagacttcccgaggaaacctgtccgttgcgttgcgttgcgttgcgttgcgttgcgttgc
 45 gatgttt
 50 tt
 55 tt

agatgggtttcagtgaaagatgtggtagttgagaactaaaaagtgaacattgaaacatcgacgtaactggaaa
ccg (SEQ ID NO:4)

5

The amino acid sequences of human PDGF-A, PDGF-B, PDGF-C and PDGF-D are represented below:

PDGF-A (GenBank entry # NM_002607)

10 MRTLACLLLLGCGYLAHVLAEEAEIPREVIERLARSQIHSIRDLQRLLEIDSGSEDSDLTSLRAHGVHATKHVP
EKRPLPIRRKRSIEEAVPAVCKTRTVIYEIPRSQVDPTSANFLIWPPCVEVKRCTGCCNTSSVKCQPSRVHRSV
KVAKVEYVRKKPKLKEVQVRLEEHLECACATTSLNPDYREEDTGRPRESGKKRKRKRLKPT (SEQ ID NO:5)

15 **PDGF-B (GenBank entry # NM_002608)**

20 MNRCWALFLSLCCYLRLVSAEGDPIPEELYEMSDHSIRSFDDLQRLLHGDPGEEDGAEL
DLNMTRSHSGGELESLARGRSLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLV
WPPCVEQRCSCGCNNRNVQCRPTQVQLRPVQVRKIEIVRKPKIFKKATVTLEDHLACKC
ETVAAARPVTSPGGSQEQRAKTPQTRVTIRTVRVRPPKGKHKRKFHKHTDKTALKETLG
A (SEQ ID NO:6)

PDGF-C (GenBank entry # AF260738)

25 MSLFGLLLLTSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDPQHERIITVSTNGSIHSPRFHTYPRTNTVLVW
RLVAVEENWVWIQLTFDERFGLEDPEDDICKYDFVVEEPESDGTILGRWCGSGTVPGKQISKGNQIRIRFVSDYEYF
PSEPGFCIHYNIVNMPQFTEAVSPSVLPPSALPLDLLNNAITAFSTLEDIRYLEPERWQLDLEDLYRPTWQLLGK
AFVFGRKSRVVDLNLLTEEVRLYSCTPRNFSVSIREELKRTDTIFWPGCLLVKRCGGNCACCLHNCNECQCVP SK
VTKKYHEVLQLRPKTGVRLHKS LTDVALEHHHECDCVCRGSTGG (SEQ ID NO:7)

30

PDGF-D (GenBank entry # AF336376)

35 MHRLIFVYTLICANFCSCRDTSATPQSASIKALRNANLRRDESNHLDLYRRDETIQVKGNGYVQSPRFPN SYPR
NLLLTWRLHSQENTRIQLVFDNQFGLEEAENDICRYDFVEVEDISETSTIIRGRWCGHKEVPPRIKSRTNQIKIT
FKSDDYFVAKPGFKIYYSLLEDFQPAASETNWEVTSSISGVSYNSPSVTDPTLIADALDKIAEFDTVEDLLK
YFNPESWQEDLENMYLDTPRYRGRSYHDRKSKVLDRLNDDAKRYSCTPRNYSVNIREELKLANVFFPRCLLVQ
RCGGNC CGT VNR SCT CNG KTVKKYHEVLQFEPGHIKRRG RAKT M ALVDIQLDH HERCDC CICSSR PPR (SEQ
ID NO:8)

40

VEGF Receptors and their Ligands

The growth of new blood vessels from existing endothelium (angiogenesis) is tightly controlled in healthy adults by opposing effects of positive and negative regulators. Under certain pathological conditions, including proliferative retinopathies, rheumatoid arthritis, psoriasis and cancer, positive regulators prevail and angiogenesis contributes to disease progression (reviewed in Folkman (1995) *Nature Medicine* 1:27-31). In cancer, the notion that angiogenesis represents the rate limiting step of tumor growth and metastasis (Folkman 50 (1971) *New Engl. J. Med.* 285:1182-1186) is now supported by considerable experimental

evidence (reviewed in Aznavoorian et al. (1993) *Cancer* 71:1368-1383; Fidler and Ellis (1994) *Cell* 79:185-188; Folkman (1990) *J. Natl. Cancer Inst.* 82:4-6).

A number of angiogenic growth factors have been described to date among which vascular endothelial growth factor (VEGF) appears to play a key role as a positive regulator 5 of physiological and pathological angiogenesis (reviewed in Brown et al.(1996) *Control of Angiogenesis*(Goldberg and Rosen, eds.) Birkhauser, Basel, in press; Thomas (1996) *J. Biol. Chem.* 271:603-606). VEGF is a secreted disulfide-linked homodimer that selectively stimulates endothelial cells to proliferate, migrate, and produce matrix-degrading enzymes (Conn et al.(1990) *Proc. Natl. Acad. Sci. USA* 87:1323-1327); Ferrara and Henzel (1989) 10 *Biochem. Biophys. Res. Commun.* 161:851-858); Gospodarowicz et al.(1989) *Proc. Natl. Acad. Sci. USA* 73:7311-7315); Pepper et al.(1991) *Biochem. Biophys. Res. Commun.* 181:902-906; Unemori et al.(1992) *J. Cell. Physiol.* 153:557-562), all of which are processes required for the formation of new vessels. In addition to being the only known endothelial cell specific 15 mitogen, VEGF is unique among angiogenic growth factors in its ability to induce a transient increase in blood vessel permeability to macromolecules (hence its original and alternative name, vascular permeability factor, VPF) (Dvorak et al.(1979) *J. Immunol.* 122:166-174; Senger et al.(1983) *Science* 219:983-985; Senger et al.(1986) *Cancer Res.* 46:5629-5632). Increased vascular permeability and the resulting deposition of plasma proteins in the extravascular space assists the new vessel formation by providing a provisional matrix for the 20 migration of endothelial cells (Dvorak et al.(1995) *Am. J. Pathol.* 146:1029-1039). Hyperpermeability is indeed a characteristic feature of new vessels, including those associated with tumors (Dvorak et al.(1995) *Am. J. Pathol.* 146:1029-1039). Furthermore, compensatory angiogenesis induced by tissue hypoxia is also now known to be mediated by 25 VEGF (Levy et al.(1996) *J. Biol. Chem.* 274:2746-2753); Shweiki et al. (1992) *Nature* 359:843-845).

VEGF occurs in four forms (VEGF-121, VEGF-165, VEGF-189, VEGF-206) as a result of alternative splicing of the VEGF gene (Houck et al. (1991) *Mol. Endocrin.* 5:1806-1814; Tischer et al. (1991) *J. Biol. Chem.* 266:11947-11954). The two smaller forms are diffusible while the larger two forms remain predominantly localized to the cell membrane as 30 a consequence of their high affinity for heparin. VEGF-165 also binds to heparin and is the most abundant form. VEGF-121, the only form that does not bind to heparin, appears to have a lower affinity for the receptors (Gitay-Goren et al. (1996) *J. Biol. Chem.* 271:5519-5523) as well as lower mitogenic potency (Keyt et al. (1996) *J. Biol. Chem.* 271:7788-7795).

VEGF₁₆₅ is the most predominant protein, but transcripts of VEGF₁₂₁ may be more abundant.

VEGF₂₀₆ is rarely expressed and has been detected only in fetal liver. Recently, other splice variants of 145 and 183 aa have also been described. The 165, 189 and 206 aa splice variants have heparin-binding domains, which help anchor them in extracellular matrix and are involved in binding to heparin sulfate and presentation to VEGF receptors. This binding is a key factor for VEGF potency (*i.e.*, the heparin-binding forms are more active). Several other members of the VEGF family have been cloned, including VEGF-B, -C, and -D. Placenta growth factor (PIGF) is also closely related to VEGF-A. VEGF-A, -B, -C, -D, and PIGF are all distantly related to platelet-derived growth factors-A and -B.

Most types of cells, but usually not endothelial cells themselves, secrete VEGF.

Currently, three high-affinity tyrosine kinase receptors for VEGF have been identified, of which VEGF receptor (VEGF)-Flk-1/KDR (VEGFR-2) is exclusively expressed in vascular endothelial cells. Vascular endothelial growth factor (VEGF) was originally discovered as an endothelial-specific growth factor. The biological effects of VEGF are mediated by two tyrosine kinase receptors (Flt-1 and Flk-1/KDR) whose expression is highly restricted to cells of endothelial origin (de Vries et al. (1992) *Science* 255:989-991; Millauer et al. (1993) *Cell* 72:835-846; Terman et al. (1991) *Oncogene* 6:519-524). While the expression of both functional receptors is required for high affinity binding, the chemotactic and mitogenic signaling in endothelial cells appears to occur primarily through the KDR receptor (Park et al. (1994) *J. Biol. Chem.* 269:25646-25654; Seetharam et al. (1995) *Oncogene* 10:135-147; Waltenberger et al. (1994) *J. Biol. Chem.* 269:88-26995). The importance of VEGF and VEGF receptors for the development of blood vessels has recently been demonstrated in mice lacking a single allele for the VEGF gene (Carmeliet et al. (1996) *Nature* 380:435-439; Ferrara et al. (1996) *Nature* 380:439-442) or both alleles of the Flt-1 (Fong et al. (1995) 376:66-70) or Flk-1 genes (Shalaby et al. (1995) *Nature* 376:62-66). In each case, distinct abnormalities in vessel formation were observed resulting in embryonic lethality.

VEGF is produced and secreted in varying amounts by virtually all tumor cells (Brown et al. (1997) *Regulation of Angiogenesis* (Goldberg and Rosen, Eds.) Birkhäuser, Basel, pp.233-269). Direct evidence that VEGF and its receptors contribute to tumor growth was recently obtained through a demonstration that the growth of human tumor xenografts in nude mice could be inhibited by neutralizing antibodies to VEGF (Kim et al. (1993) *Nature* 362:841-844), by the expression of dominant-negative VEGF receptor Flk-1 (Millauer et al. (1996) *Cancer Res.* 56:1615-1620; Millauer et al. (1994) *Nature* 367:576-579), by low molecular weight inhibitors of Flk-1 tyrosine kinase activity (Strawn et al. (1996) *Cancer Res.* 56:3540-3545) or by the expression of antisense sequence to VEGF mRNA (Saleh et al.

(1996) *Cancer Res.* 56:393-401). Importantly, the incidence of tumor metastases was also found to be dramatically reduced by VEGF antagonists (Claffey et al. (1996) *Cancer Res.* 56:172-181).

In addition to their use as anticancer agents, VEGF inhibitors may be useful in a wide variety of proliferative diseases characterized by excessive angiogenesis, including psoriasis, ocular disorders, collagen vascular diseases and rheumatoid arthritis. Although most tumor types are known to produce VEGF, until recently none has been shown to express functional VEGF receptors.

While the predominant role of this growth factor in the formation of new blood vessels is unquestioned, recent observations indicate that VEGF also has direct effects on neurons and glial cells, and stimulates their growth, survival and axonal outgrowth. Because of these pleiotropic effects, VEGF has now been implicated in several neurological disorders both in the preterm infant (leukomalacia) and the adult (stroke, neurodegeneration, cerebral and spinal trauma, ischemic and diabetic neuropathy, nerve regeneration). It is not known if the effect of VEGF in these disorders relates to its angiogenic activity or direct neurotrophic effect.

It is known that VEGF is involved in the formation of new blood vessels during embryonic development as well as in a variety of pathological conditions. Although VEGF primarily stimulates endothelial cells, it may also act on other cell types. Indeed, VEGF, Flt-1 and Flk-1 have recently been implicated in stroke, spinal cord ischemia and in ischemic and diabetic neuropathy.

The nucleic acid sequence for human VEGF-165 (GenBank # AF486837) is represented below:

25 ATGAACTTCTGCTGTCTGGGTGCATTGGAGCCTTGCCTGCTGCTCTACCTCCACCAT
GCCAAGTGGTCCCAGGCTGCACCCATGGCAGAAGGAGGGCAGAACATCACGAAAGTG
GTGAAGTTCATGGATGTCTATCAGCGCAGCTACTGCCATCCAATCGAGAACCTGGTGGAC
ATCTTCCAGGAGTACCCCTGATGAGATCGAGTACATCTTCAAGCCATCCTGTGTGCCCTG
ATGCGATGCGGGGGCTGCTGCAATGAGGAGGGCTGGAGTGTTGTGCCCCACTGAGGAGTCC
30 AACATCACCATGCAGATTATGCGGATCAAACCTCACCAAGGCCAGCACATAGGAGAGATG
AGCTTCCCTACAGCACAACAAATGTGAATGCAGACCAAAGAAAGATAGAGCAAGACAAGAA
AATCCCTGTGGGCCTTGCTCAGAGCGGAGAAAGCATTGTTGTACAAGATCCGCAGACG
TGTAAATGTTCTGCAAAAACACAGACTCGCGTTGCAAGGCCAGGCGAGCTTGAGTTAAC
GAACGTAATTGCAAGATGTGACAAGGCCAGGGCGGTGA

The amino acid sequence for human VEGF-165 (GenBank # AF486837) is represented below:

5 MNFLLSWVHWSLALLYLHAKWSQAAPMAEGGGQNHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKP
SCVPLMRCGGCCNDEGLECPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQENPCGPCSERR
KHLFVQDPQTCKCSCCKNTDSRCKARQLELNERTCRCDKPRR (SEQ ID NO: 3)

This invention demonstrates the functional role of VEGF for neural stem cells *in vitro* and *in vivo*. The data indicate a specific localization and function of the VEGF receptor Flk-1 in brain regions with neural stem cell activity. The VEGF-receptor Flk-1 is expressed not only in blood vessels but also in the ependymal zone of the ventricle wall, a region that is currently thought to be a possible origin for neural stem cells. VEGF exerts a strong influence on neural stem cell activity by increasing the generation of new neurons in the hippocampus and the olfactory bulb, when directly applied to the adult rodent brain. Neural stem cell cultures express VEGF as well as its receptor Flk-1, suggesting an autocrine role of VEGF in cultured neural stem cells. Using defined cell culture medium, it is shown that VEGF enhances the expansion of neural stem cells *in vitro*.

The invention provides a method of activating a receptor on a neural stem cell. The method comprises exposing a neural stem cell expressing a receptor to exogenous reagent, which induces the neural stem cell to proliferate, differentiate or migrate.

This invention can be practiced using stem cells of various types. Neural stem cells and progenitor cells can be obtained from any mammal, as well as fetal or adult tissue. In a preferred embodiment, the mammal is a human. NSCs/NPCs can be derived from central nervous system tissue selected from the group consisting of the hippocampus, ventricle wall, neocortex, cerebellum, septal and striatal parenchymal, basal forebrain, hindbrain, mesencephalon, diencephalon, septum and spinal cord. In a preferred embodiment, the NSC/NPC is derived from the ventricle wall.

Neither the PDGF nor VEGF families are limited to the disclosed nucleic acid and amino acid sequences. Other sequences can be retrieved from GenBank including, for example, the GenBank entry numbers: NM002607, NM033023, M12783, AF486837, AF024710, AK098750, AF022375, NM_003376, M27281, M32977, AY047581, AF430806, X62568, AF091352, AF214570, AB021221, AJ010438, S85192, BC019867, BC011177, AK056914 and AF062645.

Production of Reagents

Reagents for treatment of patients are recombinantly produced, purified and formulated according to well known methods.

Reagents of the invention, and individual moieties or analogs and derivatives thereof, 5 can be chemically synthesized. A variety of protein synthesis methods are common in the art, including synthesis using a peptide synthesizer. See, *e.g.*, *Peptide Chemistry, A Practical Textbook*, Bodasnsky, Ed. Springer-Verlag, 1988; Merrifield, *Science* 232: 241-247 (1986); Barany, *et al.*, *Intl. J. Peptide Protein Res.* 30: 705-739 (1987); Kent, *Ann. Rev. Biochem.* 57:957-989 (1988), and Kaiser, *et al.*, *Science* 243: 187-198 (1989). The peptides are purified 10 so that they are substantially free of chemical precursors or other chemicals using standard peptide purification techniques. The language "substantially free of chemical precursors or other chemicals" includes preparations of peptide in which the peptide is separated from chemical precursors or other chemicals that are involved in the synthesis of the peptide. In one embodiment, the language "substantially free of chemical precursors or other chemicals" 15 includes preparations of peptide having less than about 30% (by dry weight) of chemical precursors or non-peptide chemicals; more preferably less than about 20% chemical precursors or non-peptide chemicals, still more preferably less than about 10% chemical precursors or non-peptide chemicals, and most preferably less than about 5% chemical precursors or non-peptide chemicals.

20 Chemical synthesis of peptides facilitates the incorporation of modified or unnatural amino acids, including D-amino acids and other small organic molecules. Replacement of one or more L-amino acids in a peptide with the corresponding D-amino acid isoforms can be used to increase the resistance of peptides to enzymatic hydrolysis, and to enhance one or more properties of biologically active peptides, *i.e.*, receptor binding, functional potency or 25 duration of action. See, *e.g.*, Doherty, *et al.*, 1993. *J. Med. Chem.* 36: 2585-2594; Kirby, *et al.*, 1993, *J. Med. Chem.* 36:3802-3808; Morita, *et al.*, 1994, *FEBS Lett.* 353: 84-88; Wang, *et al.*, 1993 *Intl. J. Pept. Protein Res.* 42: 392-399; Fauchere and Thiunieau, 1992. *Adv. Drug Res.* 23: 127-159.

30 Introduction of covalent cross-links into a peptide sequence can conformationally and topographically constrain the peptide backbone. This strategy can be used to develop peptide analogs of reagents with increased potency, selectivity and stability. A number of other methods have been used successfully to introduce conformational constraints into peptide sequences in order to improve their potency, receptor selectivity and biological half-life. These include the use of (*i*) C_α-methylamino acids (see, *e.g.*, Rose, *et al.*, *Adv. Protein Chem.*

37: 1-109 (1985); Prasad and Balaram, *CRC Crit. Rev. Biochem.*, 16: 307-348 (1984));
(ii) N_α-methylamino acids (see, e.g., Aubry, *et al.*, *Int. J. Pept. Protein Res.*, 18: 195-202
(1981); Manavalan and Momany, *Biopolymers*, 19: 1943-1973 (1980)); and
(iii) α,β-unsaturated amino acids (see, e.g., Bach and Gierasch, *Biopolymers*, 25: 5175-S192
5 (1986); Singh, *et al.*, *Biopolymers*, 26: 819-829 (1987)). These and many other amino acid
analogs are commercially available, or can be easily prepared. Additionally, replacement of
the C-terminal acid with an amide can be used to enhance the solubility and clearance of a
peptide.

Alternatively, a reagent may be obtained by methods well-known in the art for
10 recombinant peptide expression and purification. A DNA molecule encoding the protein
reagent can be generated. The DNA sequence is known or can be deduced from the protein
sequence based on known codon usage. See, e.g., Old and Primrose, *Principles of Gene
Manipulation* 3rd ed., Blackwell Scientific Publications, 1985; Wada *et al.*, *Nucleic Acids
Res.* 20: 2111-2118(1992). Preferably, the DNA molecule includes additional sequence, e.g.,
15 recognition sites for restriction enzymes which facilitate its cloning into a suitable cloning
vector, such as a plasmid. Nucleic acids may be DNA, RNA, or a combination thereof.
Nucleic acids encoding the reagent may be obtained by any method known within the art
(e.g., by PCR amplification using synthetic primers hybridizable to the 3'- and 5'-termini of
the sequence and/or by cloning from a cDNA or genomic library using an oligonucleotide
20 sequence specific for the given gene sequence, or the like). Nucleic acids can also be
generated by chemical synthesis.

Any of the methodologies known within the relevant art regarding the insertion of
nucleic acid fragments into a vector may be used to construct expression vectors that contain
a chimeric gene comprised of the appropriate transcriptional/translational control signals and
25 reagent-coding sequences. Promoter/enhancer sequences within expression vectors may use
plant, animal, insect, or fungus regulatory sequences, as provided in the invention.

A host cell can be any prokaryotic or eukaryotic cell. For example, the peptide can be
expressed in bacterial cells such as *E. coli*, insect cells, fungi or mammalian cells (such as
Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to
30 those skilled in the art. In one embodiment, a nucleic acid encoding a reagent is expressed in
mammalian cells using a mammalian expression vector. Examples of mammalian expression
vectors include pCDM8 (Seed (1987) *Nature* 329:840) and pMT2PC (Kaufman *et al.* (1987)

EMBO J 6: 187-195). Furthermore, transgenic animals containing nucleic acids that encode PDGF may also be used to express peptides of the invention.

The host cells, can be used to produce (*i.e.*, overexpress) peptide in culture.

Accordingly, the invention further provides methods for producing the peptide using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding the peptide has been introduced) in a suitable medium such that peptide is produced. The method further involves isolating peptide from the medium or the host cell. Ausubel *et al.*, (Eds). In: *Current Protocols in Molecular Biology*. J. Wiley and Sons, New York, NY. 1998.

An "isolated" or "purified" recombinant peptide or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the peptide of interest is derived. The language "substantially free of cellular material" includes preparations in which the peptide is separated from cellular components of the cells from which it is isolated or recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of peptide having less than about 30% (by dry weight) of peptide other than the desired peptide (also referred to herein as a "contaminating protein"), more preferably less than about 20% of contaminating protein, still more preferably less than about 10% of contaminating protein, and most preferably less than about 5% contaminating protein. When the peptide or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the peptide preparation.

The invention also pertains to variants of a reagent that function as either agonists (mimetics) or as antagonists. Variants of a reagent can be generated by mutagenesis, *e.g.*, discrete point mutations. An agonist of a reagent can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the reagent. An antagonist of the reagent can inhibit one or more of the activities of the naturally occurring form of the reagent by, for example, competitively binding to the receptor. Thus, specific biological effects can be elicited by treatment with a variant with a limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the reagent has fewer side effects in a subject relative to treatment with the naturally occurring form of the reagent.

Preferably, the analog, variant, or derivative reagent is functionally active. As utilized herein, the term "functionally active" refers to species displaying one or more known functional attributes of a full-length reagent. "Variant" refers to a reagent differing from naturally occurring reagent, but retaining essential properties thereof. Generally, variants are 5 overall closely similar, and in many regions, identical to the naturally occurring reagent.

Variants of the reagent that function as either agonists (mimetics) or as antagonists can be identified by screening combinatorial libraries of mutants of the reagent for peptide agonist or antagonist activity. In one embodiment, a variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a 10 variegated gene library. A variegated library of variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential sequences is expressible as individual peptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display) containing the set of sequences therein. There are a variety of methods which can be used to produce libraries of potential variants 15 from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, 20 *e.g.*, Narang (1983) *Tetrahedron* 39:3; Itakura *et al.* (1984) *Annu Rev Biochem* 53:323; Itakura *et al.* (1984) *Science* 198:1056; Ike *et al.* (1983) *Nucl. Acids Res.* 11:477.

Derivatives and analogs of the reagent or individual moieties can be produced by various methods known within the art. For example, the polypeptide sequences may be modified by any number of methods known within the art. See *e.g.*, Sambrook, *et al.*, 1990. 25 *Molecular Cloning: A Laboratory Manual*, 2nd ed., (Cold Spring Harbor Laboratory Press; Cold Spring Harbor, NY). Modifications include: glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, linkage to an antibody molecule or other cellular reagent, and the like. Any of the numerous chemical modification methodologies known within the art may be utilized including, but not limited 30 to, specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH₄, acetylation, formylation, oxidation, reduction, metabolic synthesis in the presence of tunicamycin, *etc.*

Derivatives and analogs may be full length or other than full length, if said derivative or analog contains a modified nucleic acid or amino acid, as described *infra*. Derivatives or

analogs of the reagent include, but are not limited to, molecules comprising regions that are substantially homologous in various embodiments, of at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or preferably 95% amino acid identity when: (i) compared to an amino acid sequence of identical size; (ii) compared to an aligned sequence in that the alignment is done 5 by a computer homology program known within the art (e.g., Wisconsin GCG software) or (iii) the encoding nucleic acid is capable of hybridizing to a sequence encoding the aforementioned peptides under stringent (preferred), moderately stringent, or non-stringent conditions. See, e.g., Ausubel, *et al.*, *Current Protocols in Molecular Biology*, John Wiley and Sons, New York, NY, 1993.

10 Derivatives of the reagent may be produced by alteration of their sequences by substitutions, additions or deletions that result in functionally-equivalent molecules. One or more amino acid residues within the reagent may be substituted by another amino acid of a similar polarity and net charge, thus resulting in a silent alteration. Conservative substitutes for an amino acid within the sequence may be selected from other members of the class to 15 which the amino acid belongs. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. Positively charged (basic) amino acids include arginine, lysine and histidine. Negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

20 The reagent can be administered locally to any loci implicated in the CNS disorder pathology, *i.e.* any loci deficient in neural cells as a cause of the disease. For example, the reagent can be administered locally to the ventricle of the brain, substantia nigra, striatum, locus ceruleous, nucleus basalis Meynert, pedunculopontine nucleus, cerebral cortex, and spinal cord.

25 Neural stem cells and their progeny can be induced to proliferate and differentiate *in vivo* by administering to the host a reagent, alone or in combination with other agents, or by administering a pharmaceutical composition containing the reagent that will induce proliferation and differentiation of the cells. Pharmaceutical compositions include any substance that blocks the inhibitory influence and/or stimulates neural stem cells and stem 30 cell progeny to proliferate and ultimately differentiate. Such *in vivo* manipulation and modification of these cells allows cells lost, due to injury or disease, to be endogenously replaced, thus obviating the need for transplanting foreign cells into a patient.

Antibodies

Included in the invention are antibodies to be used as reagents. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, *i.e.*, molecules that contain an antigen binding site that 5 specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F_{ab} , $F_{ab'}$ and $F_{(ab')2}$ fragments, and an F_{ab} expression library. In general, antibody molecules obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature 10 of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG₁, IgG₂, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, 15 subclasses and types of human antibody species.

An isolated protein of the invention intended to serve as an antigen, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that 20 immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein and encompasses an epitope thereof such that an antibody 25 raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are 30 hydrophilic regions.

In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of PDGF, VEGF or a PDGF or VEGF receptor that is located on the surface of the protein, *e.g.*, a hydrophilic region. A hydrophobicity analysis of the human 35 those protein sequences will indicate which regions of the polypeptide are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, *e.g.*, Hopp and Woods, 1981, *Proc. Nat. Acad. Sci. USA*

78: 3824-3828; Kyte and Doolittle 1982, *J. Mol. Biol.* 157: 105-142, each incorporated herein by reference in their entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

5 The term "epitope" includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. A PDGF or VEGF ligand or receptor polypeptide or a fragment thereof 10 comprises at least one antigenic epitope. An anti-PDGF or VEGF antibody of the present invention is said to specifically bind to the antigen when the equilibrium binding constant (K_D) is $\leq 1 \mu\text{M}$, preferably $\leq 100 \text{ nM}$, more preferably $\leq 10 \text{ nM}$, and most preferably $\leq 100 \text{ pM}$ to about 1 pM, as measured by assays such as radioligand binding assays or similar assays known to those skilled in the art.

15 Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, *Antibodies: A Laboratory Manual*, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are 20 discussed below.

Polyclonal Antibodies

For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native 25 protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples 30 of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols,

polyanions, peptides, oil emulsions, dinitrophenol, *etc.*), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

5 The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (*e.g.*, from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be
10 immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

15 Monoclonal Antibodies

The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of
20 the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, *Nature*, 256:495 (1975). In a hybridoma method, a mouse,
25 hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized *in vitro*.

The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell
30 (Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-

103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, 5 immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high 10 level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for 15 the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for 20 the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by 25 the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). It is an objective, especially important in therapeutic applications of monoclonal antibodies, to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.

After the desired hybridoma cells are identified, the clones can be subcloned by 30 limiting dilution procedures and grown by standard methods (Goding, 1986). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures

such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, *Nature* 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

20

Humanized Antibodies

The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeyen et al., *Science*, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies

can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin 5 and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992)).

10 Human Antibodies

Fully human antibodies essentially relate to antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell 15 hybridoma technique (see Kozbor, et al., 1983 *Immunol Today* 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. *Proc Natl Acad Sci USA* 80: 20 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc., pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, *J. Mol. Biol.*, 227:381 (1991); 25 Marks et al., *J. Mol. Biol.*, 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. 30 This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (*Bio/Technology* 10, 779-783 (1992)); Lonberg et al. (*Nature* 368 856-859 (1994)); Morrison (*Nature* 368, 812-13 (1994)); Fishwild et al, (*Nature Biotechnology* 14, 845-51 (1996)); Neuberger (*Nature*

Biotechnology 14, 826 (1996)); and Lonberg and Huszar (Intern. Rev. Immunol. 13 65-93 (1995)).

Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's 5 endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human 10 DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the XenomouseTM as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human 15 immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the 20 antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent 25 No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable 30 marker.

A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light

chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that 5 binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

F_{ab} Fragments and Single Chain Antibodies

According to the invention, techniques can be adapted for the production of 10 single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F_{ab} expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F_{ab} fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the 15 idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F_(ab')₂ fragment produced by pepsin digestion of an antibody molecule; (ii) an F_{ab} fragment generated by reducing the disulfide bridges of an F_(ab')₂ fragment; (iii) an F_{ab} fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F_v fragments.

20

Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is 25 any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different 30 specificities (Milstein and Cuello, Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished

by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion 5 preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co- 10 transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least 15 a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or 20 threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab')₂ bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies 25 can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')₂ fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the 30 Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Additionally, Fab' fragments can be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby et al., *J. Exp. Med.* 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')₂ molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., *J. Immunol.* 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., *Proc. Natl. Acad. Sci. USA* 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., *J. Immunol.* 152:5368 (1994). Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., *J. Immunol.* 147:60 (1991).

Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc γ R), such as Fc γ RI (CD64), Fc γ RII (CD32) and Fc γ RIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA or TETA.

Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

Immunoliposomes

5 The antibodies disclosed herein can also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

10 Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction.

Antibody Therapeutics

20 Antibodies of the invention, including polyclonal, monoclonal, humanized and fully human antibodies, may be used as therapeutic agents such as one of this invention. Such agents will generally be employed to treat or prevent a disease or pathology, specifically neurological disease, in a subject. An antibody preparation, preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody 25 molecule and the target antigen in question. In the first instance, administration of the antibody may abrogate or inhibit the binding of the target with an endogenous PDGF or VEGF ligand to which it naturally binds. In this case, the antibody binds to the target and masks a binding site of the naturally occurring ligand, wherein the ligand serves as an effector molecule. Thus, the receptor mediates a signal transduction pathway for which 30 ligand is responsible.

 Alternatively, the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule. In this case the target, a PDGF or VEGF receptor having an endogenous ligand which needs to be modulated,

binds the antibody as a surrogate effector ligand, initiating a receptor-based signal transduction event by the receptor.

A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological response. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen and the rate at which an administered antibody is depleted from the free volume of the subject to which it is administered.

10

Diseases and Disorders

Diseases and disorders that are characterized by altered (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with therapeutics that antagonize (*i.e.*, reduce or inhibit) or activate PDGF or VEGF activity.

15

Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (*i*) an aforementioned peptide, analog, derivatives, fragments or homologs thereof; (*ii*) antibodies to an aforementioned peptide; (*iii*) nucleic acids encoding an aforementioned peptide; (*iv*) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (*i.e.*, due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to "knockout" endogenous function of an aforementioned peptide by homologous recombination (*see, e.g.*, Capecchi, 1989. *Science* 244: 1288-1292); or (*v*) modulators (*i.e.*, inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

20

Diseases and disorders that are characterized by altered (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with therapeutics that increase (*i.e.*, are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, analog, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

25

Increased or decreased levels can be detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (*e.g.*, from biopsy tissue) and assaying it *in vitro* for RNA or

peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (e.g., by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, 5 etc.) and/or hybridization assays to detect expression of mRNAs (e.g., Northern assays, dot blots, *in situ* hybridization, and the like).

Therapeutic Methods

Another aspect of the invention pertains to methods of modulating PDGF and VEGF 10 expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of PDGF and/or VEGF protein activity associated with the cell. An agent that modulates this protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a PDGF or VEGF receptor, a peptide, a PDGF or 15 VEGF peptidomimetic, or other small molecule. In one embodiment, the agent stimulates the activity of the PDGF or VEGF signalling pathway. Examples of such stimulatory agents include active PDGF and VEGF protein and a nucleic acid molecule encoding PDGF or VEGF that has been introduced into the cell. In another embodiment, the agent inhibits 20 PDGF or VEGF signaling. Examples of such inhibitory agents include antisense nucleic acid molecules and antibodies. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a 25 disease or disorder, specifically a neurological disorder. In one embodiment, the method involves administering an reagent (e.g., an reagent identified by a screening assay described herein), or combination of reagents that modulate (e.g., up-regulates or down-regulates) PDGF and VEGF expression or activity. In another embodiment, the method involves administering a PDGF and VEGF protein or nucleic acid molecule as therapy to modulate proliferation, differentiation or survival of NSCs/NPCs.

Stimulation of PDGF or VEGF activity is desirable in situations in which PDGF 30 and/or VEGF are abnormally downregulated and/or in which increased PDGF or VEGF activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., Parkinson's disease and Alzheimer's disease). As shown in Example 5, PDGF-BB can counteract the MPTP-induced neuronal loss similar to that seen in Parkinson's disease.

Determination of the Biological Effect of the Therapeutic

5 In various embodiments of the invention, suitable *in vitro* or *in vivo* assays are performed to determine the effect of a specific therapeutic and whether its administration is indicated for treatment of the affected tissue.

10 In various specific embodiments, *in vitro* assays may be performed with representative stem cells or newly differentiated cells involved in the patient's disorder, to determine if a given therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for *in vivo* testing, any of the animal model system known in the art may be used prior to administration to human subjects.

Pharmaceutical Compositions

15 The invention provides methods of influencing central nervous system cells to produce progeny that can replace damaged or missing neurons in the central nervous system by exposing a patient, suffering from a neurological disease or disorder, to a reagent (e.g. PDGF, VEGF) in a suitable formulation through a suitable route of administration, that modulates NSC or NPC activity *in vivo*. A "neurological disease or disorder" is a disease or 20 disorder which results in the disturbance in the structure or function of the central nervous system resulting from developmental abnormality, disease, injury or toxin. Examples of neurological diseases or disorders include neurodegenerative disorders (e.g. associated with Parkinson's disease, Alzheimer's disease, Huntington's disease, Shy-Drager Syndrome, Progressive Supranuclear Palsy, Lewy Body Disease or Amyotrophic Lateral Sclerosis); 25 ischemic disorders (e.g. cerebral or spinal cord infarction and ischemia, stroke); traumas (e.g. caused by physical injury or surgery, and compression injuries; affective disorders (e.g. stress, depression and post-traumatic depression); neuropsychiatric disorders (e.g. schizophrenia, multiple sclerosis or epilepsy); and learning and memory disorders.

30 This invention provides a method of treating a neurological disease or disorder comprising administering a reagent that modulates neural stem cell or neural progenitor cell activity *in vivo* to a mammal. The term "mammal" refers to any mammal classified as a mammal, including humans, cows, horses, dogs, sheep and cats. In one embodiment, the mammal is a human.

The invention provides a regenerative cure for neurodegenerative diseases by stimulating ependymal cells and subventricular zone cells to proliferate, migrate and differentiate into the desired neural phenotype targeting loci where cells are damaged or missing. *In vivo* stimulation of ependymal stem cells is accomplished by locally 5 administering a reagent to the cells in an appropriate formulation. By increasing neurogenesis, damaged or missing neurons can be replaced in order to enhance brain function in diseased states.

A pharmaceutical composition useful as a therapeutic agent for the treatment of central nervous system disorders is provided. For example, the composition includes a 10 reagent of the invention, which can be administered alone or in combination with the systemic or local co-administration of one or more additional agents. Such agents include preservatives, ventricle wall permeability increasing factors, stem cell mitogens, survival factors, glial lineage preventing agents, anti-apoptotic agents, anti-stress medications, neuroprotectants, and anti-pyrogenics. The pharmaceutical composition preferentially treats 15 CNS diseases by stimulating cells (e.g., ependymal cells and subventricular zone cells) to proliferate, migrate and differentiate into the desired neural phenotype, targeting loci where cells are damaged or missing.

A method for treating a subject suffering from a CNS disease or disorder is also provided. This method comprises administering to the subject an effective amount of a 20 pharmaceutical composition containing a reagent (1) alone in a dosage range of 0.5 ng/kg/day to 500 ng/kg/day, (2) in a combination with a ventricle wall permeability increasing factor, or (3) in combination with a locally or systemically co-administered agent.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, 25 e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or 30 methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral

preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., chimeric peptide) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier

for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

10 For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

15 Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

20 The compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

25 In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to 5 produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

10 Nucleic acid molecules encoding a proteinaceous agent can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Pat. No. 5,328,470) or by stereotactic injection (see *e.g.*, Chen *et al.* (1994) PNAS 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable 15 diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

20 The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

25 In another embodiments, the reagent is administered in a composition comprising at least 90% pure reagent. The reagent can be, for example, heterodimers or homodimers of PDGF-A, PDGF-B, PDGF-AA, PDGF-BB, PDGF-AB, VEGF-A, VEGF-B, VEGF-C, VEGF-D or a PDGF or VEGF receptor, or any combination thereof.

Preferably the reagent is formulated in a medium providing maximum stability and the least formulation-related side-effects. In addition to the reagent, the composition of the invention will typically include one or more protein carrier, buffer, isotonic salt and stabilizer.

30 In some instances, the reagent can be administered by a surgical procedure implanting a catheter coupled to a pump device. The pump device can also be implanted or be extracorporeally positioned. Administration of the reagent can be in intermittent pulses or as a continuous infusion. Devices for injection to discrete areas of the brain are known in the art (see, *e.g.*, U.S. Patent Nos. 6,042,579; 5,832,932; and 4,692,147).

Reagents containing compositions can be administered in any conventional form for administration of a protein. A reagent can be administered in any manner known in the art in which it may either pass through or by-pass the blood-brain barrier. Methods for allowing factors to pass through the blood-brain barrier include minimizing the size of the factor, 5 providing hydrophobic factors which may pass through more easily, conjugating the protein reagent or other agent to a carrier molecule that has a substantial permeability coefficient across the blood brain barrier (see, *e.g.*, U.S. Patent 5,670,477).

Reagents, derivatives, and co-administered agents can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically 10 comprise the agent and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any 15 conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions. Modifications can be made to the agents to affect solubility or clearance of the peptide. Peptidic molecules may also be synthesized with D-amino acids to increase resistance to enzymatic degradation. In some cases, the composition can be 20 co-administered with one or more solubilizing agents, preservatives, and permeation enhancing agents.

For example, the composition can include a preservative or a carrier such as proteins, carbohydrates, and compounds to increase the density of the pharmaceutical composition. The composition can also include isotonic salts and redox-control agents.

25 In some embodiments, the composition administered includes the reagent and one or more agents that increase the permeability of the ventricle wall, *i.e.* "ventricle wall permeability enhancers." Such a composition can help an injected composition penetrate deeper than the ventricle wall. Examples of suitable ventricle wall permeability enhancers include, for example, liposomes, VEGF (vascular endothelial growth factor), IL-s, TNF α , 30 polyoxyethylene, polyoxyethylene ethers of fatty acids, sorbitan monooleate, sorbitan monolaurate, polyoxyethylene monolaurate, polyoxyethylene sorbitan monolaurate, fusidic acid and derivatives thereof, EDTA, disodium EDTA, cholic acid and derivatives, deoxycholic acid, glycocholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium cholate, sodium glycocholate, glycocholate, sodium

deoxycholate, sodium taurocholate, sodium glycodeoxycholate, sodium taurodeoxycholate, chenodeoxycholic acid, urosdeoxycholic acid, saponins, glycyrrhizic acid, ammonium glycyrrhizide, decamethonium, decamethonium bromide, dodecyltrimethylammonium bromide, and dimethyl- β -cyclodextrin or other cyclodextrins.

5

Drug Screening

The invention also provide a method of using the receptors or receptor/reagent complexes for analyzing or purifying certain stem or progenitor cell populations, using e.g. antibodies, against the receptors or receptor/reagent complexes.

10 In another aspect, the invention provides a method for screening for reagents that influence stem and progenitor cells. In some applications, neural cells (undifferentiated or differentiated) are used to screen factors that promote maturation into neural cells, or promote proliferation and maintenance of such cells in long-term culture. For example, candidate reagents are tested by adding them to cells in culture at varying dosages, and then

15 determining any changes that result, according to desirable criteria for further culture and use of the cells. Physical characteristics of the cells can be analyzed by observing cell and neurite growth with microscopy. The induction of expression of increased levels of proliferation, differentiation and migration can be analyzed with any technique known in the art which can identify proliferation and differentiation. Such techniques include RT-PCR, in

20 situ hybridisation, and ELISA.

25 In one aspect, novel receptor/reagents in undifferentiated neurospheres was examined using RT-PCR techniques. In particular, genes that are up-regulated in these undifferentiated neurospheres were identified. As used herein, the term "up-regulation" refers to a process that increases reagent/receptor interactions due to an increase in the number of available receptors. The presence of these genes suggests a potential role in the mediation of signal transduction pathways in the regulation of NSC/NPC function. Furthermore, by knowing the levels of expression of the receptors or their various reagents, it is possible to diagnose disease or determine the role of stem and progenitor cells in the disease. By analyzing the genetic or amino-acid sequence variations in these genes or gene products, it is possible to

30 diagnose or predict the development of certain diseases. Such analysis will provide the necessary information to determine the usefulness of using stem or progenitor cell based treatments for disease.

In another aspect, *in situ* hybridization is performed on adult mouse brain sections to determine which cells in the adult brain express these signalling pathways. This data is helpful in determining treatment options for various neurological diseases.

5 In yet another aspect, quantitative PCR is performed on RNA prepared from undifferentiated and differentiated neurospheres. In some embodiments, certain receptor-reagent combinations reveal much higher expression in the undifferentiated neurospheres as compared to neurospheres that have been induced to differentiate, while in other embodiments, other receptor-reagent combinations reveal the opposite. Undifferentiated neurospheres (which are rapidly proliferating cells with the capacity to differentiate into 10 neurons and glial cells, which express higher levels of these receptor-reagent combinations) are involved in the pathways of proliferation and differentiation of NSC/NPC. For certain signalling pathways, the data indicating that they are expressed more in differentiated neurospheres suggests a role for this receptor-reagent combination in cells embarking or proceeding on a differentiation pathway.

15 To determine the effect of a potential reagent on neural cells, a culture of NSCs/NPCs derived from multipotent stem cells can be obtained from normal neural tissue or, alternatively, from a host afflicted with a CNS disease or disorder. The choice of culture will depend upon the particular agent being tested and the effects one wishes to achieve. Once the cells are obtained from the desired donor tissue, they are proliferated *in vitro* in the presence 20 of a proliferation-inducing reagent.

25 The ability of various biological agents to increase, decrease or modify in some other way the number and nature of the stem cell progeny proliferated in the presence of the proliferative factor can be screened on cells proliferated by the methods previously discussed. For example, it is possible to screen for reagents that increase or decrease the proliferative ability of NSCs/NPCs which would be useful for generating large numbers of cells for transplantable purposes. In these studies precursor cells are plated in the presence of the reagent in question and assayed for the degree of proliferation and survival of progenitor cells and their progeny can be determined. It is possible to screen neural cells which have already been induced to differentiate prior to the screening. It is also possible to determine the effects 30 of the reagent on the differentiation process by applying them to precursors cells prior to differentiation. Generally, the reagent will be solubilized and added to the culture medium at varying concentrations to determine the effect of the agent at each dose. The culture medium may be replenished with the reagent every couple of days in amounts so as to keep the concentration of the reagent somewhat constant.

Changes in proliferation are observed by an increase or decrease in the number of neurospheres that form and/or an increase or decrease in the size of the neurospheres, which is a reflection of the rate of proliferation and is determined by the numbers of precursor cells per neurosphere.

5 Using these screening methods, it is possible to screen for potential drug side-effects on prenatal and postnatal CNS cells by testing for the effects of the biological agents on stem cell and progenitor cell proliferation and on progenitor cell differentiation or the survival and function of differentiated CNS cells.

10 Other screening applications of this invention relate to the testing of pharmaceutical compounds for their effect on neural tissue. Screening may be done either because the compound is designed to have a pharmacological effect on neural cells, or because a compound designed to have effects elsewhere may have unintended side effects on the nervous system. The screening can be conducted using any of the neural precursor cells or terminally differentiated cells of the invention.

15 Effect of cell function can be assessed using any standard assay to observe phenotype or activity of neural cells, such as receptor binding, proliferation, differentiation, survival—either in cell culture or in an appropriate model.

Therapeutic Uses

20 The fact that neural stem cells are located in the tissues lining ventricles of mature brains offers several advantages for the modification and manipulation of these cells *in vivo* and the ultimate treatment of various neurological diseases, disorders, and injury that affect different regions of the CNS. Therapy for these diseases can be tailored accordingly so that stem cells surrounding ventricles near the affected region would be manipulated or modified 25 *in vivo* using the methods described herein. The ventricular system is found in nearly all brain regions and thus allows easier access to the affected areas. In order to modify the stem cells *in vivo* by exposing them to a composition comprising a reagent, it is relatively easy to implant a device that administers the composition to the ventricle and thus, to the neural stem cells. For example, a cannula attached to an osmotic pump may be used to deliver the 30 composition. Alternatively, the composition may be injected directly into the ventricles. The neural stem cell progeny can migrate into regions that have been damaged as a result of injury or disease. Furthermore, the close proximity of the ventricles to many brain regions would allow for the diffusion of a secreted neurological agent by the stem cells or their progeny.

In an additional embodiment, a reagent of the invention is administered locally, as described above, in combination with an agent administered locally or systemically. Such agents include, for example, one or more stem cell mitogens, survival factors, glial-lineage preventing agents, anti-apoptotic agents, anti-stress medications, neuroprotectants, and anti-pyrogenics, or any combination thereof.

The agent is administered systemically before, during, or after administration of the reagent of the invention. The locally administered agent can be administered before, during, or after the reagent administration.

For example, when the reagent is PDGF, stem cell mitogens, *e.g.*, EGF, FGF, VEGF, IGF-1, and insulin can be locally co-administered before, during and/or after a PDGF infusion. Additionally, in some aspects of the invention, survival factors, such as GDNF, CNTF, BDNF, NT-4, NGF, and erythropoietin can be locally co-administered before, during and/or after PDGF infusion.

For treatment of Huntington's Disease, Alzheimer's Disease, Parkinson's Disease, and other neurological disorders affecting primarily the forebrain, a reagent alone or with an additional agent or agents is delivered to the ventricles of the forebrain to affect *in vivo* modification or manipulation of the stem cells. For example, Parkinson's Disease is the result of low levels of dopamine in the brain, particularly the striatum. It is therefore advantageous to induce a patient's own quiescent stem cells to begin to divide *in vivo* and to induce the progeny of these cells to differentiate into dopaminergic cells in the affected region of the striatum, thus locally raising the levels of dopamine.

Normally the cell bodies of dopaminergic neurons are located in the substantia nigra and adjacent regions of the mesencephalon, with the axons projecting to the striatum. The methods and compositions of the invention provide an alternative to the use of drugs and the controversial use of large quantities of embryonic tissue for treatment of Parkinson's disease. Dopamine cells can be generated in the striatum by the administration of a composition comprising a reagent of the invention to the lateral ventricle.

For the treatment of MS and other demyelinating or hypomyelinating disorders, and for the treatment of Amyotrophic Lateral Sclerosis or other motor neuron diseases, a reagent of the invention, alone or with an additional agent or agents is delivered to the central canal.

In addition to treating CNS tissue immediately surrounding a ventricle, a reagent of the invention, alone or with an additional agent or agents can be administered to the lumbar cistern for circulation throughout the CNS.

In other aspects, neuroprotectants can also be co-administered systemically or locally before, during and/or after infusion of a reagent of the invention. Neuroprotectants include antioxidants (agents with reducing activity, *e.g.*, selenium, vitamin E, vitamin C, glutathione, cysteine, flavinoids, quinolines, enzymes with reducing activity, etc), Ca-channel modulators, 5 Na-channel modulators, glutamate receptor modulators, serotonin receptor agonists, phospholipids, unsaturated- and polyunsaturated fatty acids, estrogens and selective estrogen receptor modulators (SERMS), progestins, thyroid hormone and thyroid hormone-mimicking compounds, cyclosporin A and derivatives, thalidomide and derivatives, methylxanthines, MAO inhibitors; serotonin-, noradrenaline and dopamine uptake blockers; dopamine 10 agonists, L-DOPA, nicotine and derivatives, and NO synthase modulators.

Certain reagents of the invention may be pyrogenic following IV injection (*in rats*; Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000 278:R1275-81). Thus, in some aspects of the invention, antipyrogenic agents like cox2 inhibitors, indomethacin, salisyllic acid derivatives and other general anti-inflammatory/anti-pyrogenic compounds can be 15 systemically or locally administered before, during and/or after administration of the reagent of the invention.

In another aspect of the invention, anti-apoptotic agents including caspase inhibitors and agents useful for antisense-modulation of apoptotic enzymes and factors can be administered before, during, or after administration of the reagent of the invention.

20 Stress syndromes lower neurogenesis, therefore in some aspects, it may be desirable to treat a subject with anti-stress medications such as, *e.g.*, anti-glucocorticoids (*e.g.*, RU486) and beta-blockers, administered systemically or locally before, during and/or after infusion of the reagent of the invention.

25 Methods for preparing the reagent dosage forms are known, or will be apparent, to those skilled in this art.

The amount of reagent to be administered will depend upon the exact size and condition of the patient, but will be from 0.5 ng/kg/day to 500 ng/kg/day in a volume of 0.001 to 10 ml.

30 The duration of treatment and time period of administration of reagent will also vary according to the size and condition of the patient, the severity of the illness and the specific composition and method being used.

The effectiveness of each of the foregoing methods for treating a patient with a CNS disease or disorder is assessed by any known standardized test for evaluating the disease.

Other features of the invention will become apparent in the course of the following description of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof. All references, patents and patent applications cited are hereby incorporated by reference in their entirety.

EXAMPLES

Example 1: The effect of PDGFs on proliferation of cultured, non-adherent mouse neurospheres.

5

Neurosphere cultures

The anterior lateral wall of the lateral ventricle of 5-6 week old mice was enzymatically dissociated in 0.8mg/ml hyaluronidase and 0.5 mg/ml trypsin in DMEM containing 4.5 mg/ml glucose and 80units/ml DNase at 37°C for 20 min. The cells were gently triturated and mixed with three volumes of Neurosphere medium (DMEM/F12, B27 supplement, 125 mM HEPES pH7.4) containing 20 ng/ml EGF (unless otherwise stated), 100 units/ml penicillin and 100µg/ml streptomycin. After passing through a 70 µm strainer, the cells were pelleted at 160 x g for 5 min. The supernatant was subsequently removed and the cells resuspended in Neurosphere medium supplemented as above, plated out in culture dishes and incubated at 37°C. Neurospheres were ready to be split approximately 7 days after plating.

To split the neurospheres, cells were collected by centrifugation at 160 x g for 5 min. The conditioned supernatant (conditioned medium) was removed and saved. The neurospheres were resuspended in 0.5 ml Trypsin/EDTA in HBSS (1x), incubated at 37°C for 2 min and triturated gently to aid dissociation. Following a further 3 min incubation at 37°C and trituration, 3 volumes of ice cold Neurosphere medium medium w/o EGF were added to stop further trypsin activity. The cells were pelleted at 220 x g for 4 min, and resuspended in a 1:1 mixture of fresh Neurosphere medium and conditioned medium. EGF was supplemented to 20 ng/ml and the culture plated out and incubated at 37°C.

Neurosphere assays

NSCs, cultured as described above, from passage 2 were seeded in DMEM/F12 supplemented with B27 into a 96-well plate as single cells (10000 cells/well), to which agents were added at the concentrations indicated (1 nM-0,0005 nM). When cells were grown as adherent culture they were seeded in medium + B27 supplemented with 1% Fetal Calf Serum, after 6 hours when the cells had adhered, the medium was changed to serum free medium and agents were added in the same concentrations as indicated. The PDGFs used in

the in vitro experiments were human recombinant PDGF-AA and human recombinant PDGF-BB.

Intracellular ATP assay

5 Intracellular ATP levels have previously been shown to correlate to cell number (Crouch, Kozlowski et al. 1993). After 3 days of treatment, intracellular ATP was measured using the ATP SL kit (Bioluminescence) according to the manufacturer's instructions.

Results

10 In growth media supplemented with B27, PDGF-BB had a concentration dependent proliferative effect. The effect of PDGF-AA was weaker compared to BB, and when added together PDGF-AA did not alter the proliferative effect of PDGF-BB (FIG. 1). Considering the binding pattern, PDGF-AA binds only $\alpha\alpha$ PDGF receptor dimers while PDGF-BB binds all three possible combinations ($\alpha\alpha$, $\alpha\beta$ or $\beta\beta$), therefore, these results indicated that the 15 proliferative effect was due to binding to $\beta\beta$ (or $\alpha\beta$) receptors. Similar results were also obtained if cells were grown as a more differentiated adherent culture (possibly progenitor cells) on poly-d-lysine (FIG. 2).

20 **Example 2: Effects of PDGF-AA on GFAP and β -III Tubulin in mouse cultured neural stemcells/progenitors.**

NSCs, cultured as described above, were seeded from passage 2 into DMEM/F12 supplemented with B27 into a 24-well plate (poly-D-lysine-coated) as single cells (70.000 cells/well), to which PDGF-AA was added at the concentration of 1nM. The cells were then differentiated for 5 days changing medium plus/minus PDGF-AA every 48 hours. At day 6 25 the cells were harvested and Western blots were performed as described elsewhere (Patrone C et al (1999) Proc Natl Acad Sci USA. 96(19):10905-10). A neuronal marker antibody against β -III Tubulin, 1:5000 (BioSite), or a glial marker antibody against glial fibrillary acidic protein (GFAP) 1:5000, (DAKO) was used to measure phenotypic fates.

30 Under certain conditions, in adherent cultures of adult neuronal stem cells treated with PDGF-AA for 6 days there was a downregulation of GFAP in comparison to treatment with EGF (left panel). The baseline media contains EGF whereas the media for the PDGF treated cells contain both EGF and PDGF. In contrast, a significant increase of the neuronal

specific β -III Tubulin marker was observed (right panel) as a response to treatment with PDGF-AA compared to treatment with EGF. This result implicates PDGF-AA in differentiation of neural stem cells into neurons. Sample loads were normalized to protein and DNA content.

5 In another set of experiments the effects of PDGF-AA were studied with immunocytochemical methods in fixed adherently cultured neural stem cells. In these experiments a similar result to the Western-study was observed, e.g., an upregulation of β -III Tubulin and a down regulation of GFAP (FIG. 3). In other experiments with PDGF-AA, analyzed by immunocytochemistry, it was shown that the factor caused a general shift from a
10 stem cell phenotype to a progenitor phenotype in that cultures contained both of the markers, GFAP and β -III Tubulin. However, in all instances there was no overlap between markers, suggesting that PDGF-AA promotes differentiation to both glial and neural lineages via distinct pathways (FIG. 4). In concurrent experiments the effect of PDGF-BB was also studied. Similar effects as those observed with AA was obtained with BB (data not shown).

15

Example 3: The effect of PDGF-AA and PDGF-BB on neural differentiation (III Tubulin) of mouse neural stem cells.

Differentiation

20 Adult mouse neurospheres were dissociated with trypsin (Gibco) into single cells and transferred to poly-D-Lysine plates (BD) in the above culture medium, without growth factors, supplemented with 1% Fetal Calf Serum (Gibco). The cells were incubated over night to adhere to the plate. The medium was changed to culture medium, without growth factors, supplemented with 1nM PDGF-AA or PDFG-BB (both from R&D Systems). The
25 medium with new substance added every second day. The cells were incubated for a total of 7 days.

Immunohistochemistry

The cells were washed two times with PBS (Gibco) and fixed for 15min RT with 4% Formaldehyde (Sigma) and permeabilized 20min RT in 0,1% Triton X-100 (Sigma) in PBS.

30 After fixation and permeabilization the cells were labelled with mouse monoclonal anti- β -III Tubulin (1:500 Promega). Primary antibody was visualized with anti mouse Texas-Red (1:100 Vector Laboratories). All antibodies were diluted in PBS with 0.1% Triton X-100.

Protein expression analysis with Western Blot

The cells were washed twice with PBS (Gibco) and lysed with 200ul lysis buffer/well. The lysis buffer contained PBS, 0,1% Triton X-100, 1mM EDTA and 1 tabl. Protease inhibitor cocktail (Roche). The samples were run on a 4-12% Bis-Tris gel (Novex) under reduced conditions with MOPS buffer (Novex) and blotted onto a Hybond ECL nitrocellulose membrane (Amersham Biotech). Blocked in 5% ECL-Block (Amersham Biotech) in PBS + 0.1% Tween 20 (Sigma). The membranes were labelled with mouse monoclonal anti- β -III Tubulin (1:5000 Promega). The primary antibody was detected using a secondary antibody anti-mouse-HRP (1:10000 Amersham Biotech) and ECL Plus+ Western Blot Detection Kit (Amersham Biotech). All antibodies were diluted in PBS with 0.1% Triton X-100, 1% ECL Block. The signal were then captured on ECL Hyper Film (Amersham Biotech)

As measured qualitatively (FIG. 5) and quantitatively (FIG. 6), PDGF-AA and PDGF-BB trigger neuronal differentiation of cultured mouse neural stem cells/progenitors.

15

Example 4. In vivo neurogenic action of BB in healthy rats after ICV infusion.

Male rats (12 hours light /dark regime; feeding and drinking ad libitum; 5 animals in standard cage) were infused (Alzet minipumps) in the left lateral ventricle with human recombinant PDGF-BB for 7 days at a daily dose of 36 ng/day (8 animals/group). Human recombinant BDNF (brain derived neurotrophic factor) was used as a positive control (Pencea V et al., J. Neurosci Sept 1 (2001), 21(17):6706-17). Bromodeoxyuridine (BrdU) was also included in the infusion vehicle (artificial cerebrospinal fluid) to enable measurement of proliferation by quantitation of BrdU incorporation in the DNA. Animals were sacrificed at 7 (proliferation) or 28 days (neurogenesis) after start of treatment and brains were dissected and prepared for sectioning and immunohistochemistry (Pencea V et al., J. Neurosci Sept 1 (2001), 21(17):6706-17).

Proliferation was measured by BrdU incorporation and diaminobenzidine (DAB) staining of HRP conjugated secondary antibodies (FIG. 7). Cells were counted in a phase contrast microscope. Neural phenotype was assessed by staining for neuronal marker NeuN by immunocytochemistry using a fluorescence readout. The secondary antibodies were labeled with FITC or Alexa Fluor568. In double staining analyses designed to measure neurogenesis, BrdU and NeuN were quantitated by fluorescence (above) and counting of cells was done in a confocal microscope. For further experimental details, see Pencea V et al., J. Neurosci Sept 1 (2001), 21(17):6706-17. A number of brain regions were analysed.

7-day group (proliferation)

Table 1: PDGF-BB increased proliferation of the ventricle wall in comparison to vehicle-treated animals.

5 The mean values of two sections, m3x600 micrometer counted along the lateral ventricle wall were the following (mean+/-sem):

	<u>Condition:</u>	<u>Cell count:</u>	
10	vehicle	134+/-10	
	PDGF-BB	216+/-25	(p<0.05 to vehicle,
ANOVA)			
	reference compound (BDNF)	177+/-15	(p<0.05 to vehicle,
ANOVA)			

15 In the dentate gyrus of the hippocampus and the olfactory bulb there was no significant effect recorded on the proliferation marker BrdU by either compound. A nonsignificant tendency towards more BrdU cells (proliferation) were recorded (Table 1).

28-day group (neurogenesis)

20 In BrdU labeling analyses, in the dentate gyrus, the CA1 and the alveus there was no significant effect of PDGF or BDNF, rather a (non-significant) tendency for decrease of BrdU positive cells in comparison to vehicle-treated animals (not shown).

Double labeling analyses revealed that the ratio of NeuN positive cells to BrdU positive cells was similar (no significant difference) in all three groups in all areas 25 investigated (dentate gyrus, CA1, alveus, subventricular zone, striatum) (not shown).

In the subventricular zone there was a slight effect of BDNF to increase the number of proliferating cells. PDGF had no such statistically significant effect (not shown).

30 In the striatum there was a significant increase in BrdU positive cells after infusion of PDGF-BB and BDNF in comparison to vehicle-treated animals (Table 2, FIG. 8). The results revealed that vehicle and factor groups show the same ratio of double labelled cells, it is concluded that infusion of PDGF-BB (and BDNF) significantly increase neurogenesis in the striatum in comparison to vehicle treated animals.

Table 2: The effect of PDGF-BB on BrdU positive cells in the striatum.

35 Cells were counted in 300x300 μ m squares

Vehicle	10.6+4.2
PDGF-BB	40+6.8 (p<0.01 to vehicle, ANOVA)
BDNF	39.8+7.3 (p<0.01 to vehicle, ANOVA)

In the striatum there was a gradient of BrdU-labeled cells from ventricle to cortex which indicates that the cells may originate from the subventricular zone. In the CA1/alveus region no such gradient was observed.

5 **Example 5: PDGF-BB counteracts MPTP-induced neuronal loss in substantia nigra pars compacta.**

Animals

10 Ten-week old male C57Bl/6 mice (25 g, B&K Universal, Stockholm, Sweden).

Drug delivery

15 PDGF-BB (Sigma) was administered directly into the right lateral ventricle of the brain using osmotic pumps (Alza 1003D, delivery of 1.0 μ l/h for three days) and brain infusion kits. The drug solution was prepared as follows: 10 μ g PDGF-BB was dissolved in 10 μ l 1M HAc, after which pH was adjusted to 7.4 by adding 10 μ l NaOH. A buffer was added (100ml 0.01M PBS containing 5 mg/ml BSA and 20 mM Hepes) to a final volume of 4,000 μ l. Each minipump was connected to a brain infusion needle, which was stereotactically placed in the right lateral ventricle of the mouse brain in deeply anesthetized mice (chloral 20 hydrate 60 mg/kg intraperitoneal). The pump was placed subcutaneously in the neck. The delivery rate of PDGF-BB was 0.1 μ g/h/kg body weight. 3 H-thymidine (6.7 Ci/ml, NEN) was given for three days via another Alzet pump which was placed intraperitoneally.

One hour after the pumps were inserted, the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP HCl, Sigma) was given subcutaneously (40 mg/kg).

25 Two months later, animals were anesthetized with choral hydrate (60 mg/kg ip) and sacrificed by intracardial infusion of fixative (4 % paraformaldehyde in 0.1 M phosphate buffered saline (PBS) containing 0.4 % picric acid. After dissection, postfixation in the same fixative continued for 1.5 h followed by cryoprotection. After dissection of the midbrain, the two sides of the brain were separated with a cut along the ventro-dorsal midline and the tissue 30 was postfixated in the same solution and cryoprotected in sucrose. Cryostat sections were prepared as follows: a randomly chosen half-brain was cut into 40 μ m thick sections through the full rostro-caudal extension of substantia nigra pars compacta. A randomly chosen series of every 6th section was taken to perform free-floating immunohistochemistry using a polyclonal anti-tyrosine hydroxylase antibody (diluted 1:400, Pel-Freez) in order to identify 35 dopaminergic neurons in the tissue. To visualize the antibody, the avidin-biotin peroxidase kit (Vector) with 0.03% DAB as chromagen was used adding 0.01% H₂O₂. Cresyl violet was employed to identify the nucleolus, Nissl substance and glia cells (Chan et al., 1997; Walters

et al., 1999). The other half of the brain was sectioned in 10 μ m thick sections on glass and a randomly chosen series of every 6th section was immunohistochemically stained for tyrosine hydroxylase in dopaminergic neurons as previously described. To detect incorporation of the ³H-thymidine nucleotide in brain cells, the sampled slides were dipped in NTB2 nuclear track emulsion (Kodak) and stored in light-tight boxes at -20 °C for four weeks. The granular black label was developed in D-19 (Kodak, diluted 1:2 with d.w. at 16-18 °C).

Analysis

The total number of dopaminergic neurons in the substantia nigra pars compacta was estimated with an optical fractionator using a 100x oil immersion objective to detect the neuronal sampling unit, the nucleolus (Janson and Møller, 1993)(coefficient of error for each estimate was <0.09). Volume of the neurons was estimated with the rotator in vertical sections (Janson and Møller, 1993). Proliferation of new neurons was shown as black dots over cells where the radioactive nucleotide was incorporated.

15

Infusion of PDGF causes nigral neurons to proliferate

PDGF-BB completely counteracted the MPTP-induced loss of tyrosine hydroxylase positive nerve cells after an MPTP lesion. Mice were lesioned with MPTP and treated with PDGF. Neurons of the substantia nigra were stained with Nissl stain and then counted.

20 Animals were also infused with tritiated thymidine in order to allow for measurement of proliferation. Upon the analysis of the number of cells in the substantia nigra in the MPTP lesioned mice after infusion of PDGF, not only did the cell number in the structure double but cells were also positive for proliferation. For example, neural cells of the substantia nigra had also incorporated tritiated thymidine in their nuclei as shown by observing black

25 autoradiographic grains over nuclei of Nissl stained cells. Quantitative results are summarized in Table 3.

30 **Table 3: Total number of tyrosine hydroxylase neurons in the bilateral substantia nigra pars compacta in MPTP-lesioned animals treated with PDGF-BB intraventricularly.**

35 Saline (n=6)	11,900 \pm 100
PDGF-BB (n=3)	12,300 \pm 300
MPTP+Saline (n=6)	5,500 \pm 700*
MPTP+PDGF-BB (n=3)	10,000 \pm 200

Mean \pm S.E.M, number of animals in each group within parenthesis. Statistical analysis was performed with ANOVA followed by Scheffe's post-hoc test. * = P<0.001, different from all other animal groups. For details on animals and treatment, see text.

5

In the PDGF-BB+MPTP group, the size of the nigral dopamine neurons varied substantially. Whereas some neurons were found to be greater than the usual size of dopamine neurons (FIG. 9), others were instead unusually small (FIG. 10). The former may represent stimulation of neuronal growth in neurons surviving the lesion, whereas the latter, 10 small bipolar tyrosine hydroxylase positive neurons, may result from a process where new nerve cells are recruited to the nigral neuronal population from progenitor cells. Stimulation of proliferation of NSCs/NPCs as well as enhanced migration into substantia nigra and differentiation into a dopaminergic phenotype is suggested to be the mechanism for the increased cell numbers in the lesioned animals treated with PDGF-BB. The involvement of 15 increased proliferation in the increased cell numbers is indicated by the finding of a granular black label representing 3 H-thymidine over nigral nerve cells (FIG. 11).

Example 6: PDGFR-A and PDGFR-B genes are expressed in cultured Human Neural Stem Cells.

20 **Human Stem Cell (HSC) Cultures**

A biopsy from the anterior lateral wall of the lateral ventricle was taken from an adult human patient and enzymatically dissociated in PDD (Papain 2.5U/ml; Dispase 1U/ml; DNase I 250 U/ml) in DMEM containing 4.5 mg/ml glucose and 37°C for 20 min. The cells were gently triturated and mixed with three volumes of Human Stem Cell Plating Medium 25 (HSCPM) (DMEM/F12; 10% FBS). The cells were pelleted at 250 x g for 5 min. The supernatant was subsequently removed and the cells resuspended in HSCPM, plated out on fibronectin coated culture dishes and incubated at 37°C in 5% CO₂. The following day the expansion of the culture was initiated by change of media to HSC culture media (DMEM/F12; BDNF 9500; EGF 20ng/ml; FGF2 20ng/ml). The HSC were split using trypsin 30 and EDTA under standard conditions. FBS was subsequently added to inhibit the reaction and the cells collected by centrifugation at 250 x g for 5 min. The HSC were replated in HSC culture media.

RT-PCR

The following primer pairs were designed to specifically identify the presence of *pdgfr-a*, and *pdgfr-b* gene expression in HSC cultures. Estimated band sizes for each primer pair are given below:

			Band size (base pairs)
5	PDGFR-A	aaccgtgtataagt caggggaaacg (SEQ ID NO:9) Ccgcacctctacaacaaaatgtttg (SEQ ID NO:10)	355
10		Aaccgtgtataagt caggggaaacg (SEQ ID NO:11) Tggccactgtcttcttccttagca (SEQ ID NO:12)	507
15	PDGFR-B	gtctctgtgaacgcagtgcagactg (SEQ ID NO:13) Gcaaattgttagtgtgcccacctct (SEQ ID NO:14)	338
20		Gtctctgtgaacgcagtgcagactg (SEQ ID NO:15) Aggcctcgaacactacacctgcagtg (SEQ ID NO:16)	382

HSC were prepared and cultured as stated above. Total RNA isolated using Qiagen's RNeasy Mini Kit according to the manufacturer's instructions and DNase treated using Ambion Dnase I and according to protocol. Life Technology's One-Step RT-PCR Kit was used to 25 detect the presence of *pdgfr-a* and *pdgfr-b* mRNA. Briefly, 50ng of total RNA was used in each reaction, with an annealing temperature of 54°C. To further ensure that genomic contamination of the total RNA did not give rise to false positive results, an identical reaction in which the RT-taq polymerase mix was replaced by taq polymerase alone and was run in parallel with the experimental RT-PCR. The reactions were electrophoresed on a 1.5% 30 agarose gel containing ethidium bromide and the bands visualised under UV light.

RT-PCR was performed on total RNA prepared from cultured HSC using primer pairs specific for the above genes (FIG. 12). The bands indicated with a white arrow correspond to the bands of the desired size (PDGFR-A [lane1 355bp; lane2 507bp], PDGFR-B [lane3 338bp; lane4 382bp]), verifying that they represent correct product. A parallel control experiment without using any reverse transcriptase, only taq polymerase, ruled out false positive bands through genomic contamination.

Example 7: The effects of i.c.v. infused PDGF-BB in 6-OHDA lesioned rats.

BDNF, which has been previously shown to increase neurogenesis in the normal intact brain (Pencea et al., 2001), was used as a reference compound. Both PDGF and BDNF increased the numbers of newly formed cells in the substantia nigra and striatum at 12 weeks 5 following treatment, as detected with BrdU-staining. At 5 weeks after treatment, neuronal phenotyping of BrdU-labeled cells with NeuN in the striatum revealed a significant increase in newly generated neurons.

Animals and surgical procedures

10 Animal handling and surgical procedures were carried out according to the ethical and regulatory permits set forth by Jordbruksverket and Lund University. Adult female Sprague-Dawley rats (B&K Universal AB) rats weighing 220-250 g, were housed in pairs with a 12 h light-dark cycle with free access to food and water. To lesion the substantia nigra, rats were fixed into a stereotaxic frame and 6-OHDA (3 mg in 0.02% ascorbate saline, Sigma) was 15 injected at a rate of 1 μ l / min in 2 deposits of 2 and 2.5 μ l into the right ascending mesostriatal forebrain bundle at the following coordinates: 4.4 mm caudal to bregma, 1.2 mm lateral to midline, 7.8 mm below dura; 4.0 mm caudal, 0.8 mm lateral, 8.0 mm below dura, respectively (Paxinos and Watson, 1998). Three weeks after 6-OHDA injections, the completeness of the lesion was assessed with the amphetamine-induced rotation test. D- 20 methylamphetamine (2.5 mg, i.p.) was injected 5 min prior to placing the rat in an automated rotormeter bowl that measured the number of rotations over 90 min. Rats that exhibited over 5 net ipsilateral (to the lesioned hemisphere) turns per min advanced to the next phase of the study to have osmotic minipumps implanted.

25 Before implantation, an Alzet Model 2002 osmotic minipump (200 μ l; flow rate: 0.5 μ l/h, 12 μ l/day) was prefilled with 200 μ l of compound solution (see below) and placed in a NaCl (0.9%) solution warmed in water bath (37°C) 36 hrs before implantation. Rats were anesthetized with halothane in a mixture of nitrous oxide/oxygen (70:30) and maintained with 2-3% halothane. For implantation, rats were placed in a stereotaxic frame and the cannula of the Alzet Brain Infusion kit II was placed into the right lateral ventricle (coordinates: AP = - 30 0.3 mm posterior bregma, L = 1.5 mm lateral to satura sagittalis, 4.5 mm the dura; Paxinos and Watson, 1998), and secured to the skull with screws and dental cement. The minipump was then placed subcutaneously in the mid-scapular region. The scalp was treated with lidocaine gel before suturing. Twelve days after insertion, the rats were briefly anaesthetized

with halothane in order to remove the pump. Removed pumps had the remaining solution volume and weight recorded.

Growth factors and experimental design

5 The effects of infused PDGF-BB and BDNF following 6-OHDA lesions were investigated at 2 different time points: at 12 days or 5 weeks after minipump insertion. Rats receiving human PDGF-BB (order # 220-BB-050; 50 µg, R&D Systems) each had 36 ng/d of PDGF dissolved in 0.1 M PBS (3 µg/ml). Rats receiving human recombinant BDNF (order # 248-BD-025; 25 µg, R&D Systems) each had 12 ng/d of BDNF dissolved in 0.1 M PBS
10 (1 µg/ml). BrdU was co-administered with the compound solution in the minipumps by dissolving it into the 0.1 M PBS medium. Control rats received only BrdU / PBS infusions.

Tissue processing and immunohistochemistry

15 Brain tissue was obtained by anesthetizing the rat and transcardially perfusing with 0.9% saline followed by 4% paraformaldehyde (PFA). Brains were stored PFA for 2 hours, then transferred to 20% sucrose PBS and sectioned coronally on a sledge microtome at 30 µm thickness. Free-floating sections were stored in Walter's antifreeze solution at 4 °C until staining.

20 To detect for newly generated BrdU-positive cells, sections were incubated for 30 min in 2 M HCl at 37 °C to denature DNA, and subsequently incubated in blocking serum (5 % normal horse serum in 0.1 M PBS containing 0.25% Triton X-100 for 1 hr). Following blocking, incubation of monoclonal rat anti-BrdU antibody (Harlan Sera Lab, UK) in 2 % blocking solution occurred at a dilution of 1:100 at 4 °C for 36 hrs. The sections were then incubated with biotin-horse-anti-mouse antibody (1:200) (Vector, CA) in 2 % blocking
25 solution for 2 hr and visualized with DAB-NiCl Vectastain Elite kit. The procedure for doubling labeling of BrdU with NeuN or TH was similar, except that a monoclonal rat anti-BrdU antibody (1:100; Sigma, Sweden) was incubated either with a monoclonal mouse anti-NeuN antibody (1:100; Chemicon, USA) or with a monoclonal anti-TH antibody (1:1000; Pelfreeze) in the appropriate 2 % blocking solution in the dark for 36 to 48 hrs. For
30 immunofluorescent visualization, sections were incubation in secondary antibodies: Cy3-conjugated donkey anti-rat (1:200; Jackson ImmunoResearch, PA) for BrdU; a biotinylated horse anti-mouse antibody (1:200; BA2001, Vector, CA) for NeuN; and a FITC-conjugated goat anti-rat (1:200;) for TH. After 2 hrs of incubation at room temperature, a further 2 hr incubation with Alexa Fluor 488 conjugated goat anti-mouse secondary antibody (1:200;

Molecular Probes, Netherlands) for NeuN was required. All sections were mounted onto glass slides and cover slipped with Prolong Antifade mounting medium (Molecular Probes).

Quantitative analyses

5 All analyses were conducted by an observer blind to the treatment conditions. In the substantia nigra, the number of BrdU-labeled cells was determined with conventional epifluorescence or light microscopy with a 40x objective. All cells were counted bilaterally from 5 to 7 coronal sections per rat, located between 4.8 to 6.0 mm posterior to bregma. All counts were pooled together for each rat and are reported as mean number of cells per

10 lesioned substantia nigra.

In the striatum, the number of BrdU-labeled cells was determined using stereological cell number and volume estimations. Three sections, taken from 10 parallel series of 30 μ m thick coronal sections located between 1.6 mm anterior to 0.2 mm posterior to bregma, were analyzed for each rat. A modified optical fractionator method (Gundersen&Jensen1987) was employed, with an 40 x objective fitted on an Olympus BH-2 microscope, a X-Y-Z step motor stage run by a PC computer, a CCD-IRIS color video camera, and CAST-GRID software (Olympus, Denmark). For systematic sampling, the frame area and counting interval was set to allow for at least 200 cells to be sampled from each region of interest. The optical dissector was set to sample all cells below the first 2 μ m from the surface of the section.

15 20 For the longer delay time groups (5 weeks) co-localization of BrdU-positive cells with TH in the substantia nigra, and NeuN in the striatum, was assessed using a confocal scanning light microscope (Leica DM IRE3 microscope, Leica Confocal Software Version 2.77). Fifty cells from the lesioned hemisphere were analyzed for each rat, from the same regions where BrdU cell counts were conducted.

25 Statistical analyses were performed by ANOVA, with alpha set at 0.05.

Newly generate cells in the striatum

30 Substantial numbers of BrdU labelled cells were observed in the 6-OHDA denervated striatum (27-fold greater than non-lesioned hemisphere). Both PDGF and BDNF treatment significantly elevated the numbers of BrdU labelled cells in the denervated striatum as compared to PBS infusion (FIG. 13), with no differences between the two growth factors (FIG. 14). These significant increases in cell numbers were primarily observed at 12 days after infusion, such that only the BDNF rats exhibited significant increases at 5 weeks. At

Week 5, there was no statistically significant differences in the proportion of newly generated neurons, such that: 15.3 % of PBS, 16.6 % of BDNF, and 20.9 % of PDGF treated rats had BrdU cells in the striatum co-labelled with NeuN. Importantly, when estimating the absolute number of BrdU / NeuN double labelled cells, PDGF and BDNF treatment was found to have 5 generated significantly more neurons (FIG. 15).

Newly generate cells in the substantia nigra

Substantial numbers of BrdU labelled cells were observed in both the lesioned and non-lesioned substantia nigra; however, the lesioned hemisphere had significant more cells 10 (30 % over non-lesioned side). Despite the infusions of growth factors being made into the lateral ventricle (over 5 mm distance from the substantia nigra), both PDGF and BDNF treatment significantly elevated the numbers of BrdU labelled cells in the lesioned nigra as compared to PBS treatment, with no differences between the two growth factors (FIG. 16). These significant increases in cell numbers were only observed at 12 days after infusion, and 15 not at 5 weeks.

Overall, it was found that the administration of PDGF to a damaged brain can induce newly formed cells to migrate and differentiate to neurons in the denervated striatum, and potentially into the damaged substantia nigra as well. These promising results support the therapeutic use of PDGF to restore neurons lost in Parkinson's disease.

20

Example 8: Localization of the VEGF receptor Flk-1 in the ventricle wall of the adult brain.

FIG. 17 depicts neurogenesis in the hippocampus which is characterized by proliferative clusters of cells along the border between the granule cell layer (g) and the hilus 25 region (h). These cells begin to migrate into the granule cell layer about 1 week after their last cell division and can be colabeled with markers for granule cells (e.g., NeuN and Calbindin). The VEGF receptor Flk-1 is highly expressed in the lateral dentate gyrus and ventricle wall (FIGS. 18 and 19, respectively). Immunostaining suggested localization in the ependymal layer (FIGS. 18 and 19). Ependymal cells also express Notch-1, which plays an 30 important role in determining the neural fate of ectodermal cells (Johansson et al., 1999). Isolated individual ependymal cells can form neural stem cell (neurospheres) in culture (Johansson et al., 1999).

Example 9: Stimulation of adult neurogenesis by VEGF-Infusion.

In a first experiment it was shown that neuronal production in the adult hippocampus is stimulated by infusion of VEGF into the lateral ventricle. Here, proliferating cells were labeled with BrdU during 7 days of continuous VEGF infusion. Four weeks later, when the 5 newborn cells have differentiated into granule cells, a marked increase in BrdU labeled cells is observed in the dentate gyrus (FIG. 20). It can be inferred from this result that VEGF is a potent activator of neurogenesis in the adult brain.

Example 10: Expression of VEGF and Flk-1 in neural stem cell cultures.

10 In order to analyze the functional consequences of VEGF stimulation in culture, it is important to know whether Flk-1 is expressed in neural stem cell cultures. Using RT-PCR we were recently able to show that neural stem cell cultures (neurospheres) from the ventricle wall and from the hippocampus express VEGF mRNA (FIG. 21) and Flk-1 mRNA (FIG. 22). Moreover, VEGF release was detected by Elisa assay (FIG. 23). This result shows that 15 VEGF has an autocrine function in neural stem cell cultures. In FIG. 21, it was described, by using RT-PCR, that isoforms of VEGF are expressed by neurospheres when cultured in the presence of EGF and FGF. GADPH was used as a quality control of the mRNA.

Example 11: VEGF in neural stem cell cultures.

20 Neural stem cells were prepared according to the attached protocol. Cells were grown in serum-free medium, subcloned and used between passage 6 and 10. If not otherwise mentioned the experiments consisted of triplets for analysis and were independently repeated at least 3 times.

25 **Basal medium:** Neurobasal medium (NB, Gibco BRL) & B27 supplement (Gibco BRL).

Growth medium: NB, B27 supplement + 20ng/ml of FGF-2 (R&D Systems) + 20ng/ml EGF (R&D Systems) + 2 μ g/ml heparin (Sigma, Germany).

Cells were plated in Growth medium at 10.000 cells/ml and after 2 days switched to the 30 experimental condition. Cells were kept under the experimental condition for 7 days.

VEGF (mouse recombinant VEGF₁₆₄) was used at 50 ng/ml.

VEGF-receptor inhibitor PADQ (4-[(4-Chloro-2-fluoro)phenylamino-6,7-dimethoxyquinazoline, Calbiochem): A potent inhibitor of VEGF receptor (Flt-1 and Flk-1) tyrosine kinase activity. IC50 = 2.0 mM and 0.1 mM for Flt-1 and Flk-1, respectively.

5 VEGFR-Inhibitor was used at 100 nM (IC50 for flk-1)

VEGF-receptor inhibitor SU1498 - (E)-3-(3,5-Diisopropyl-4-hydroxyphenyl)-2-[(3-phenyl-n-propyl)amino-carbonyl]acrylonitrile (Calbiochem): A potent and selective inhibitor of the vascular endothelial growth factor (VEGF) receptor kinase Flk-1 (IC50 = 700 nM).

10 SU1498 has only a weak inhibitory effect on PDGF-receptor (IC50 >50 mM), EGF-receptor (IC50 >100 mM), and HER2 (IC50 >100 mM) kinases.
SU1498 was used at 700 nM (IC50 for Flk-1).

Cell culture methods

15 **Primary cell cultures for growing spheres of neural stem cells from adult lateral ventricle wall**

Adult female Fischer-344 rats (3-4 months; Charles River, Germany) were killed via cervical dislocation, the brains of each rat were removed and stored at 4°C in DPBS (PAN, Germany) with 4.5g/L glucose (Merck, Germany) (DPBS/glu). Overlying meninges and 20 blood vessels were removed. Ependymal zone including subependymal/subventricular zone form the lateral wall of the lateral ventricle were aseptically removed. The dissected tissue was transferred to fresh DPBS/glu, washed once, transferred to petri-dishes and dissociated mechanically into a single cell suspension. The cell suspension was washed in DPBS/glu in order to rinse off excess blood and resuspended in PPD-solution containing 0.01% Papain 25 (Worthington Biochemicals, England), 0.1% dispase II (Boehringer, Germany), 0.01% DNase I (Worthington Biochemicals, England) and 12.4mM MgSO₄ in HBSS (PAN, Germany) without Mg⁺⁺/Ca⁺⁺ (PAA, Germany) and digested for 30 to 40 min at room temperature. The cell solution was triturated every 10 min. Dissociated cells were collected and resuspended in serum-free DMEM/F12 medium containing 2mM L-glutamine and 30 0.1g/L penicillin/streptomycin and washed three times with accurate trituration with a blue tip. Finally the single cell suspension was resuspended in Neurobasal medium (Gibco BRL, Germany) supplemented with B27 (Gibco BRL, Germany) (NB/B27), 2mM L-glutamine (PAN, Germany), 0.1g/L penicillin/streptomycin (PAN, Germany), 2μg/ml heparin (Sigma,

Germany), 20ng/ml bFGF-2 (R&D Systems, Germany) and 20ng/ml EGF (R&D Systems, Germany). Live cells were counted by trypan blue exclusion assay in a hemocytometer. Cells were seeded in T-25 culture flasks and cultures were maintained at 37°C in an incubator with 95% air, 5% CO₂. Single cells began to form spheres within 5 to 7 days of suspension culture 5 and continued to grow in mass and number over the next weeks. Media were changed every 7 days.

Passaging of cells

The culture medium containing floating neurospheres was collected in a 15ml 10 centrifuge tube and centrifuged at 800rpm. The pellet was resuspended in 200µl of Accutase (Innovative Cell Technologies Inc., USA, distributed by PAA, Germany) and triturated about 10 times using a pipette. Then, the cell suspension was incubated at 37°C for 10 min. Dissociated spheres were again triturated and resuspended in 800µl of NB/B27 medium. An aliquot was counted by trypan blue exclusion assay in a hemocytometer to determine the 15 amount of live and dead cells. 1 x 10⁵ cells were plated in T75 culture flasks for long term passaging (10ml of culture medium per flask) in NB/B27 medium. The cells obtained after Accutase-treatment of primary neurospheres proliferated and yielded secondary neurospheres. Secondary neurospheres were passaged 7 to 9 days after plating primary 20 neurosphere cells. Similar to primary cultures and primary neurospheres, single cells obtained after dissociation of secondary neurospheres proliferated and yielded tertiary neurospheres.

Proliferation test

Various media and supplements were used to study the most optimal conditions for neural stem cell cultures. Neurobasal medium (Gibco BRL, Germany) or DMEM/F12 (1:1) 25 medium (PAN, Germany) were either supplemented with B27 (Gibco BRL, Germany), N2 (Gibco BRL, Germany), or BIT9500 (StemCell Technologies Inc., Canada). Human low density lipoproteins (LDL, Sigma, Germany) were added to the BIT9500-containing media at a final concentration of 40µg/µl according to the manufacturer. All media contained 2mM L-glutamine, 0.1g/L penicillin/streptomycin, 2µg/ml heparin (Sigma, Germany), 20ng/ml bFGF 30 (R&D Systems, Germany), and 20ng/ml EGF (R&D Systems, Germany). 1 x 10⁴ cells per well were seeded in 12-well plates in a volume of 1ml and grown under standard conditions. At day 7 the grown neurospheres were counted, dissociated by Accutase and live cells were counted by trypan blue exclusion assay in a hemocytometer.

BrdU ELISA

Neural stem cell were plated at 10000 cells/ml well and cultured for 7 days during which VEGF, PADQ or SU 1498 were added every second day. 24 hr before DNA isolation cells were pulsed with 5 μ M BrdU. Cells were harvested and resuspended in 200 μ l PBS.

5 After treatment with 4 μ l RNase (100mg/ml, Roche), DNA was isolated using the DNeasy KIT (Qiagen). After determining the concentration, DNA was treated with 0.25 M NaOH for 30 min. followed by 0.25 M HCL and buffering with 0.2 M KH₂PO₄ (pH 7). DNA was transferred to 96 wells plates (DNA Binding Plates, Costar) in a concentration series starting at 2ng/ μ l and were incubated over night in the presence of 50 mM Na₂HPO₄. After washing 10 in PBS, unspecific binding to the wells was blocked with 3% BSA/PBS for 30 min. With intermittent washes in PBS, a mouse anti BrdU antibody (Roche-Boehringer, 1:500) was incubated for 1 hr, followed by incubation with donkey- anti mouse POD (Jackson, 1:1000) for 1 hr. After PBS rinses developing reagent OPD was applied for 1 hr and the optical density was determined at 450 nm.

15

Clonally-derived cultures

The *in vitro* effect of VEGF was analyzed using neural stem cells isolated from the lateral ventricle wall of the adult rat brain. Previously reported *in vitro* data on VEGF was derived from primary cultures. The analysis has now been repeated and extended using 20 clonally-derived neural stem cells, thus excluding the possibility that VEGF acts on non-stem cell derived cells which could be present in the primary cell preparation. These clonally derived neural stem cells are multipotent and produce the three major cell types of the brain: neurons, astrocytes and oligodendrocytes (Figure 26).

25 **VEGF stimulation in neural stem cell cultures**

VEGF has a dose-dependent stimulatory effect on the proliferation of neural stem cells from the adult rat brain (FIG. 24). Since VEGF can act via several receptors, two VEGF isoforms were compared, which have different receptor affinity. VEGF-A₁₆₅ can bind to flk-1, flt-1 and neuropilin-1 whereas VEGF-A₁₂₁ can only bind to the Flk-1 receptor. Both 30 isoforms showed a significant stimulation of neural stem cell cultures, suggesting that the proliferation-enhancing effect of VEGF in neural stem cell cultures is mainly mediated by Flk-1 signaling (FIG. 25).

VEGF effects on neural stem cell expansion

When VEGF was added to the growth medium which already contains EGF and FGF-2 as mitogens, a 2.5 fold increase in the number of cells was observed after 7 days. The ED50 is in the range of 10ng/ml and maximal stimulation was reached at 50 ng/ml (FIG. 27). VEGF
5 is therefore a potent co-factor for the expansion of neural stem cell cultures.

When VEGF was added to the basal medium, a 5-fold increase in the number of cells was detected after 7 days (FIG. 28, left panel). Two VEGF receptor tyrosine kinase inhibitors were effective in blocking the VEGF effect at their respective ED50 concentration for Flk-1 (FIG. 28, left panel). These compounds were used at concentrations which specifically block
10 the VEGF receptor Flk-1. Under growth conditions (Basal medium+EGF+FGF-2+heparin) the VEGF receptor antagonists were also able to block the effect of the exogenously applied VEGF (FIG. 28, right panel).

Endogenous VEGF expression and release

15 It has been previously shown that Flk-1 is expressed in neural stem cell cultures. When determining the expression and release of VEGF into the culture medium of clonally-derived neural stem cell cultures (Figure 29) it was found that rat neural stem cells are a prominent source of VEGF in comparison to other cell types, which are known to express VEGF. HUVEC cells needed about 8 days to produce the same amount of VEGF and human
20 retinal pigment epithelial cells produced substantially less.

Since Flk-1 is present and VEGF is spontaneously released into the medium by neural stem cells, it was tested whether VEGF and its receptor Flk-1 play an endogenous role in the expansion of neural stem cell cultures. When VEGF receptor inhibitors were added to the growth medium containing recombinant EGF and FGF-2 but no recombinant VEGF, a 30%
25 reduced growth rate was observed (FIG. 30). These data suggest that EGF and FGF-2 exert their ability to expand neural stem cell cultures in part through the production and release of VEGF.

Mechanism of VEGF action in vivo

30 In order to determine whether the enhanced expansion of neural stem cultures under VEGF is due to increased proliferation or reduced cell death, neural stem cells were analyzed using a proliferation ELISA (see experimental details) and an apoptosis ELISA (Cell Death Detection ELISA, Roche Applied Sciences) according to the manufacturers protocol. Cells

grown in the presence of VEGF incorporated more BrdU and in the presence of VEGF receptor blockers less BrdU (FIG. 31), suggesting that VEGF stimulates proliferation *in vitro*.

However, using an apoptosis ELISA, an anti-apoptotic activity was also detected, since VEGF reduced the amount of DNA strand breaks, a hallmark of apoptotic cell death, whereas VEGFR blocker increased the DNA strand breaks (FIG. 32).

VEGF can exert both a proliferative and survival-promoting effect. FGF-2 has been previously shown to promote neuronal survival at a lower concentration (0.5-1ng/ml) and to promote proliferation of neural stem cells and progenitors at a higher concentration (10-20ng/ml, see Ray et al. 1993, PNAS 90:3602-3606). VEGF could act in a similar dose-dependent manner.

Increased efficiency to generate neural stem cell cultures after VEGF infusion

VEGF was infused into the lateral ventricle of adult rats. After isolating and seeding cells from the lateral ventricle wall in order to establish neural stem cell cultures, the number of spheres that formed after several weeks was significantly increased in cultures from VEGF-treated animals compared to aCSF controls (FIG. 33).

Overall, the results showed that VEGF and the VEGF receptor Flk-1 are expressed *in vivo* in close spatial relation to sites of neurogenesis. VEGF and the VEGF receptor Flk-1 are expressed *in vitro* in clonally-derived neural stem cell cultures. VEGF increased the generation of new neurons *in vivo* and the expansion of neural stem cell *in vitro*. Blocking the endogenous VEGF receptor signaling diminished the ability to expand neural stem cell cultures. Proliferation as well as cell survival were promoted by VEGF and reduced after blocking VEGF receptor signaling. It is therefore concluded that endogenously produced VEGF acts in an auto- or paracrine fashion to promote neural stem and progenitor cell growth/survival *in vitro* and the generation of neurons *in vivo*.

Example 11: Expression in Neural Stem Cells.

Human Stem Cell (HSC) Cultures

A biopsy from the anterior lateral wall of the lateral ventricle was taken from an adult human patient and enzymatically dissociated in Papain, Dispase and Dnase I in DMEM containing 4.5 mg/ml glucose and 37°C for 20 min. The cells were gently triturated and mixed with three volumes of Human Stem Cell Plating Medium (HSCPM) (DMEM/F12; 10% FBS). The cells were pelleted at 250 x g for 5 min. The supernatant was subsequently

removed and the cells resuspended in HSCPM, plated out on fibronectin coated culture dishes and incubated at 37°C in 5% CO₂. The following day the expansion of the culture was initiated by change of media to HSC culture media (DMEM/F12; BIT 9500; EGF 20ng/ml; FGF2 20ng/ml). The HSC were split using trypsin and EDTA under standard conditions. FBS 5 was subsequently added to inhibit the reaction and the cells collected by centrifugation at 250 x g for 5 min. The HSC were replated in HSC culture media.

RT-PCR

10 The following primer pairs were designed to specifically identify the presence of *vegf*, *flt-1*, *flt-4*, and *flk-1* gene expression in HSC cultures. Estimated band sizes for each primer pair are given below:

		Band size (base pairs)	
15	VEGF	ttgggtgcattggagcccttg (SEQ ID NO:17) tggccttggtgagggttgc (SEQ ID NO:18)	327
20		ttgggtgcattggagcccttg (SEQ ID NO:19) tgagcaaggcccacaggat (SEQ ID NO:20)	434
25	FLT-1	agatgtccaaataaggcacaccacgc (SEQ ID NO:21) tttcaaggcacctgctgtttcga (SEQ ID NO:22)	347
30		agatgtccaaataaggcacaccacgc (SEQ ID NO:23) ccacgagtcaaatacgcgagcaggatt (SEQ ID NO:24)	470
35	FLT-4	catccagctgtgcccagga (SEQ ID NO:25) ttcacgggcagcttaccagg (SEQ ID NO:26)	378
	FLK-1	atgatgtggttctgagtcgtctca (SEQ ID NO:27) gggggtggtaaccaaggtaactt (SEQ ID NO:28)	409
		atgatgtggttctgagtcgtctca (SEQ ID NO:29) catgccccgcttaattgtgt (SEQ ID NO:30)	476

40 Human stem cells were prepared and cultured as stated above. Total RNA isolated using Qiagen's RNeasy Mini Kit according to the manufacturer's instructions and DNase treated using Ambion Dnase I and according to protocol . Life Technology's One-Step RT-PCR Kit was used to detect the presence of *vegf*, *flt-1*, *flt-4* and *flk-1* mRNA. Briefly, 100ng of total RNA was used in each reaction, with an annealing temperature of 54°C. To further

ensure that genomic contamination of the total RNA did not give rise to false positive results, an identical reaction in which the RT-taq polymerase mix was replaced by taq polymerase alone and was run in parallel with the experimental RT-PCR. The reactions were electrophoresed on a 1.5% agarose gel containing ethidium bromide and the bands visualised
5 under UV light.

VEGF and FLT-4 genes are expressed in cultured Human Neural Stem Cells

RT-PCR was performed on total RNA prepared from cultured HSC using primer pairs specific for the above genes. The bands indicated with a white arrow correspond to the bands
10 of the desired size (VEGF [lane 1, 327bp; lane 2, 434bp], FLT-4 [lane 3, 378bp]), verifying that they represent correct product (FIG. 34). A parallel control experiment without using any reverse transcriptase, only taq polymerase, ruled out false positive bands through genomic contamination (data not shown).

15 FLT-1 and FLK-1 genes are expressed in cultured Human Neural Stem Cells

RT-PCR was performed on total RNA prepared from cultured HSC using primer pairs specific for the above genes. The bands indicated with an arrow correspond to the bands of the desired size (FLT-1 [lane 2, 470bp], FLK-1 [lane 4, 476bp]), verifying that they represent correct product (FIG. 35).

20

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention specifically described herein. Such equivalents are intended to be encompassed in the scope of the following claims.

We Claim:

1. A method of alleviating a symptom of a disease or disorder of the nervous system comprising administering PDGF, VEGF or a combination thereof to modulate neural stem cell or neural progenitor cell activity *in vivo* to a patient suffering from the disease or disorder of the nervous system.
2. The method of claim 1 wherein the PDGF, VEGF or combination thereof is administered in an amount of 0.001 ng/kg/day to 10 mg/kg/day.
3. The method of claim 1 wherein the PDGF, VEGF or combination thereof is preferably administered in an amount of 0.01 ng/kg/day to 5 mg/kg/day.
4. The method of claim 1 wherein the PDGF, VEGF or combination thereof is more preferably administered in an amount of 0.1 ng/kg/day to 1 mg/kg/day.
5. The method of claim 1 wherein the PDGF, VEGF or combination thereof is most preferably administered in an amount of 0.1 ng/kg/day to 1 μ g/kg/day.
6. The method of claim 1 wherein the PDGF, VEGF or a combination thereof is administered by injection.
7. The method of claim 6 wherein the injection is given subcutaneously, intraperitoneally, intramuscularly, intracerebroventricularly, intraparenchymally, intrathecally or intracranially.
8. The method of claim 1 wherein the PDGF, VEGF or a combination thereof is administered to the buccal, nasal or rectal mucosa.
9. The method of claim 1 wherein the PDGF, VEGF, or combination thereof is administered via peptide fusion or micelle delivery.

10. The method of claim 1 wherein the disease or disorder of the nervous system is selected from the group consisting of neurodegenerative disorders, neural stem cell disorders, neural progenitor disorders, ischemic disorders, neurological traumas, affective disorders, neuropsychiatric disorders and learning and memory disorders.
11. The method of claim 10 wherein the disease or disorder of the nervous system is selected from the group consisting of Parkinson's disease and Parkinsonian disorders, Huntington's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis, spinal ischemia, ischemic stroke, spinal cord injury and cancer-related brain/spinal cord injury.
12. The method of claim 10 wherein the disease or disorder of the nervous system is selected from the group consisting of schizophrenia and other psychoses, depression, bipolar depression/disorder, anxiety syndromes/disorders, phobias, stress and related syndromes, cognitive function disorders, aggression, drug and alcohol abuse, obsessive compulsive behaviour syndromes, seasonal mood disorder, borderline personality disorder, cerebral palsy, life style drug, multi-infarct dementia, Lewy body dementia, age related/geriatric dementia, epilepsy and injury related to epilepsy, spinal cord injury, brain injury, trauma related brain/spinal cord injury, anti-cancer treatment related brain/spinal cord tissue injury, infection and inflammation related brain/spinal cord injury, environmental toxin related brain/spinal cord injury, multiple sclerosis, autism, attention deficit disorders, nacrolepsy and sleep disorders.
13. The method of claim 1 wherein the VEGF is selected from the group consisting of VEGF-A, VEGF-B, VEGF-C and VEGF-D and the activity is proliferation or survival.
14. The method of claim 13 wherein the VEGF-A is VEGF-A₁₆₅ or VEGF-A₁₂₁.
15. The method of claim 1 wherein the PDGF is selected from the group consisting of PDGF-B, PDGF-BB, PDGF-AB, PDGF-C, PDGF-D, PDGF-CC, PDGF-DD, PDGF-BC, PDGF-AC, PDGF-AD and PDGF-BD and the activity is proliferation, differentiation or survival.

16. The method of claim 1 wherein the PDGF is PDGF-A or PDGF-AA and the activity is differentiation or survival.
17. The method of claim 1 wherein the PDGF, VEGF or combination thereof is a dimer consisting of two subunits, wherein each subunit is selected from the group consisting of PDGF A, PDGF B, PDGF C, PDGF D, VEGF A, VEGF B, VEGF C and VEGF D.
18. A method of modulating a PDGF receptor, VEGF receptor, or a combination thereof, on a neural stem cell or neural progenitor cell, the method comprising exposing the cell expressing the receptor to exogenous reagent, antibody, or affibody, wherein the exposure induces the neural stem cell or neural progenitor cell to proliferate or differentiate.
19. The method of claim 18 wherein the VEGF receptor is Flt-1, Flk-1 or Flt-4.
20. The method of claim 18 wherein the PDGF receptor is PDGF- α receptor or PDGF- β receptor.
21. The method of claim 18 wherein the reagent is selected from the group consisting of VEGF-A, VEGF-B, VEGF-C, VEGF-D, PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, PDGF-DD, PDGF-BC, PDGF-AC, PDGF-AD and PDGF-BD.
22. The method of claim 18 wherein the antibody is a monoclonal or a polyclonal antibody.
23. The method of claim 18 wherein the neural stem cell or neural progenitor cell is derived from fetal brain, adult brain, neural cell culture or a neurosphere.
24. The method of claim 18 wherein the neural stem cell or neural progenitor cell is derived from tissue enclosed by dura mater, peripheral nerves or ganglia.
25. A method of drug screening and/or drug discovery using a non-human mammal, the method comprising:
 - a. administering a PDGF or VEGF agonist to the non-human mammal; and

- b. comparing the effect of administration of the PDGF or VEGF agonist in the mammal of step (a) with a referenced non-human mammal not administered the PDGF or VEGF agonist.

26. The method of claim 25 wherein the agonist is selected from the group consisting of a peptide, small molecule, soluble receptor and receptor agonist wherein the exposure induces a neural stem cell or neural progenitor cell to proliferate or differentiate.

27. The method of claim 25 wherein the VEGF is selected from the group consisting of VEGF-A, VEGF-B, VEGF-C, VEGF-D and a combination thereof.

28. The method of claim 27 wherein the VEGF-A is VEGF-A₁₆₅ or VEGF-A₁₂₁.

29. The method of claim 26 wherein the PDGF is selected from the group consisting of PDGF-A, PDGF-B, PDGF-AA, PDGF-BB, PDGF-AB, PDGF-C, PDGF-D, PDGF-CC, PDGF-DD, PDGF-BC, PDGF-AC, PDGF-AD, PDGF-BD and a combination thereof.

30. The method of claim 26 wherein the soluble receptor is a VEGF receptor, PDGF receptor or a combination thereof.

31. The method of claim 30 wherein the VEGF receptor is selected from the group consisting of Flt-1, Flk-1 and Flt-4.

32. The method of claim 30 wherein the PDGF receptor is a PDGF- α receptor, a PDGF- β receptor or a combination thereof.

33. The method of claim 26 wherein the PDGF or VEGF agonist thereof is administered by injection.

34. The method of claim 33 wherein the injection is given subcutaneously, intraperitoneally, intramuscularly, intracerebroventricularly, intraparenchymally, intrathecally or intracranially.

35. The method of claim 26 wherein the PDGF or VEGF agonist is administered via peptide fusion or micelle delivery.
36. A method for reducing a symptom of a disease or disorder of the central nervous system in a mammal in need of such treatment comprising administering PDGF, VEGF or a PDGF or VEGF agonist to the mammal.
37. The method of claim 36 wherein the PDGF, VEGF or combination thereof is administered in an amount of 0.001 ng/kg/day to 10 mg/kg/day.
38. The method of claim 36 wherein the PDGF, VEGF or combination thereof is preferably administered in an amount of 0.01 ng/kg/day to 5 mg/kg/day.
39. The method of claim 36 wherein the PDGF, VEGF or combination thereof is more preferably administered in an amount of 0.1 ng/kg/day to 1 mg/kg/day.
40. The method of claim 36 wherein the PDGF, VEGF or combination thereof is most preferably administered in an amount of 0.1 ng/kg/day to 1 µg/kg/day.
41. The method of claim 36 wherein the reagent is selected from the group consisting of an antibody, an affibody, a small molecule and a receptor.
42. The method of claim 41 wherein the receptor is a PDGF- α receptor, PDGF- β receptor or combination thereof.
43. The method of claim 36 wherein the administration is local or systemic.
44. The method of claim 36, further comprising administering a ventricle wall permeability enhancer.
45. The method of claim 44 wherein the ventricle wall permeability enhancer is administered before, during or after administration of PDGF, VEGF or a PDGF or VEGF agonist.

46. The method of claim 44 wherein the ventricle wall permeability enhancer or the PDGF, VEGF or PDGF or VEGF agonist are admixed with a pharmaceutically acceptable carrier.
47. The method of claim 44, further comprising administration of one or more agents selected from the group consisting of stem cell mitogens, survival factors, glial-lineage preventing agents, anti-apoptotic agents, anti-stress medications, neuroprotectants, anti-pyrogenics and a combination thereof.
48. A method for inducing the *in situ* proliferation or differentiation of a neural stem cell or neural progenitor cell located in the neural tissue of a mammal, the method comprising administering a therapeutically effective amount of PDGF or VEGF to the neural tissue to induce the proliferation or differentiation of the cell.
49. The method of claim 48 wherein the PDGF is selected from the group consisting of PDGF-AA, PDGF-BB, PDGF-AB, PDGF-C, PDGF-D, PDGF-CC, PDGF-DD, PDGF-BC, PDGF-AC, PDGF-AD, PDGF-BD and a combination thereof.
50. The method of claim 48 wherein the VEGF is selected from the group consisting of VEGF-A, VEGF-B, VEGF-C and VEGF-D.
51. The method of claim 50 wherein the VEGF-A is VEGF-A₁₆₅ or VEGF-A₁₂₁.
52. The method of claim 48 wherein the administration is systemic or local.
53. The method of claim 48 wherein the administration of the PDGF, VEGF or PDGF or VEGF agonist alleviates a symptom of a disease or disorder of the nervous system.
54. The method of claim 48, further comprising administering a ventricle wall permeability enhancer.
55. The method of claim 54 wherein the ventricle wall permeability enhancer is administered before, during, or after administration of the reagent.

56. The method of claim 54 wherein the ventricle wall permeability enhancer and the PDGF, VEGF or PDGF or VEGF agonist are admixed with a pharmaceutically acceptable carrier.
57. The method of claim 54, further comprising administration of one or more agents selected from the group consisting of stem cell mitogens, survival factors, glial-lineage preventing agents, anti-apoptotic agents, anti-stress medications, neuroprotectants, anti-pyrogenics and a combination thereof.
58. A method for accelerating the growth of neural stem cells or neural progenitor cells in a desired target tissue in a subject, comprising administering intramuscularly to the subject an expression vector containing a PDGF or VEGF gene in a therapeutically effective amount.
59. The method of claim 58 wherein the expression vector is a non-viral expression vector encapsulated in a liposome.
60. A method of enhancing neurogenesis in a patient suffering from a disease or disorder of the central nervous system, by intraventricular infusion of PDGF, VEGF or PDGF or VEGF receptor agonist.
61. The method of claim 60 wherein PDGF is PDGF-AA, PDGF-BB, PDGF-AB, PDGF-C, PDGF-D, PDGF-CC, PDGF-DD, PDGF-BC, PDGF-AC, PDGF-AD, PDGF-BD and a combination thereof.
62. The method of claim 60 wherein VEGF is VEGF-A, VEGF-B, VEGF-C or VEGF-D.
63. The method of claim 62 wherein the VEGF-A is VEGF-A₁₆₅ or VEGF-A₁₂₁.
64. The method of claim 60 wherein the disease or disorder of the central nervous system is selected from the group consisting of neurodegenerative disorders, neural stem cell disorders, neural progenitor disorders, ischemic disorders, neurological traumas, affective disorders, neuropsychiatric disorders and learning and memory disorders.

65. The method of claim 60 wherein the disease or disorder of the central nervous system is selected from the group consisting of Parkinson's disease and Parkinsonian disorders, Huntington's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis, spinal ischemia, ischemic stroke, spinal cord injury and cancer-related brain/spinal cord injury.
66. The method of claim 60 wherein the disease or disorder of the central nervous system is selected from the group consisting of schizophrenia and other psychoses, depression, bipolar depression/disorder, anxiety syndromes/disorders, phobias, stress and related syndromes, cognitive function disorders, aggression, drug and alcohol abuse, obsessive compulsive behaviour syndromes, seasonal mood disorder, borderline personality disorder, Cerebral palsy, life style drug, multi-infarct dementia, Lewy body dementia, age related/geriatric dementia, epilepsy and injury related to epilepsy, spinal cord injury, brain injury, trauma related brain/spinal cord injury, anti-cancer treatment related brain/spinal cord tissue injury, infection and inflammation related brain/spinal cord injury, environmental toxin related brain/spinal cord injury, multiple sclerosis, autism, attention deficit disorders, nacrolepsy and sleep disorders.
67. A method of increasing the number of dopaminergic neurons in a patient suffering from Parkinson's disease comprising the steps of:
 - (a) infusing the patient with PDGF to a lateral ventricle of the brain;
 - (b) monitoring the patient to determine if there is proliferation and differentiation of NSCs and NPCs; and
 - (c) repeating step (a) until the desired effect is achieved.
68. The method of claim 67 wherein the PDGF is selected from the group consisting of PDGF-A, PDGF-B, PDGF-AA, PDGF-BB, PDGF-AB, PDGF-C, PDGF-D, PDGF-C, PDGF-D, PDGF-CC, PDGF-DD, PDGF-BC, PDGF-AC, PDGF-AD, PDGF-BD and a combination thereof.
69. A method for producing a population of cells enriched for human neural stem cells or human neural progenitor cells which can initiate neurospheres, comprising:

- a. contacting a population containing neural stem cells or neural progenitor cells with a reagent that recognizes a determinant on a VEGF or PDGF receptor; and
- b. selecting for cells in which there is contact between the reagent and the determinant on the surface of the cells of step (a), to produce a population highly enriched for central nervous system stem cells.

70. The method of claim 69 wherein the reagent is a reagent selected from the group consisting of a soluble receptor, a small molecule, a peptide, an antibody and an affibody.

71. The method of claim 69 wherein the VEGF receptor is selected from the group consisting of Flt-1, Flk-1 and Flt-4.

72. The method of claim 69 wherein the PDGF receptor is a PDGF- α receptor, PDGF- β receptor or combination thereof.

73. The method of claim 70 wherein the antibody is a monoclonal or a polyclonal antibody.

74. The method of claim 69 wherein the reagent is selected from the group consisting of VEGF-A, VEGF-B, VEGF-C and VEGF-D.

75. The method of claim 72 wherein the VEGF-A is VEGF-A₁₆₅ or VEGF-A₁₂₁.

76. The method of claim 70 wherein the reagent is selected from the group consisting of PDGF-A, PDGF-B, PDGF-AA, PDGF-BB, PDGF-AB, PDGF-C, PDGF-D, PDGF-CC, PDGF-DD, PDGF-BC, PDGF-AC, PDGF-AD, PDGF-BD and a combination thereof.

77. The method of claim 69 wherein the population containing neural stem cells or neural progenitor cells are obtained from any population of cells which gives rise to neural tissue.

78. The method of claim 77 wherein the neural tissue is fetal brain or adult brain.
79. A method of activating a VEGF or PDGF receptor on a neural stem cell or neural progenitor cell, the method comprising exposing a neural stem cell or neural progenitor cell expressing a receptor to exogenous reagent, antibody, or affibody, wherein the exposure induces the neural stem cell or neural progenitor cell to proliferate or differentiate.
80. The method of claim 79 wherein the VEGF receptor is Flt-1, Flk-1 or Flt-4.
81. The method of claim 79 wherein the reagent is selected from the group consisting of VEGF-A, VEGF-B, VEGF-C and VEGF-D.
82. The method of claim 81 wherein the VEGF-A is VEGF-A₁₆₅ or VEGF-A₁₂₁.
83. The method of claim 79 wherein the reagent is selected from the group consisting of PDGF-A, PDGF-B, PDGF-AA, PDGF-BB, PDGF-AB, PDGF-C, PDGF-D, PDGF-CC, PDGF-DD, PDGF-BC, PDGF-AC, PDGF-AD, PDGF-BD and a combination thereof.
84. The method of claim 79 wherein the antibody is a monoclonal or a polyclonal antibody.
85. The method of claim 79 wherein the neural stem cell or neural progenitor cell is derived from fetal brain, adult brain, neural cell culture or a neurosphere.
86. An *in vitro* cell culture comprising a cell population enriched in receptor expressing cells wherein the receptors are selected from the group consisting of Flt-1, Flk-1, Flt-4, PDGF- α and PDGF- β receptor.
87. A method for treating a disease or disorder of the central nervous system comprising administering the population of claim 86 to a mammal in need thereof.

88. A non-human mammal engrafted with the human neural stem cells or neural progenitor cells of claim 87.
89. The nonhuman mammal of claim 88 wherein the non-human mammal is selected from the group consisting of a rat, mouse, rabbit, horse, sheep, pig and guinea pig.
90. A method of reducing a symptom of a disease or disorder of the central nervous system in a subject comprising the steps of administering into the spinal cord of the subject a composition comprising a population of isolated primary neurons obtained from a fetus; and PDGF, VEGF, a PDGF or VEGF agonist or a combination thereof such that the symptom is reduced.
91. The method of claim 90 wherein the disease or disorder of the central nervous system is selected from the group consisting of neurodegenerative disorders, neural stem cell disorders, neural progenitor cell disorders, ischemic disorders, neurological traumas, affective disorders, neuropsychiatric disorders and learning and memory disorders.
92. The method of claim 90 wherein the disease or disorder of the central nervous system is selected from the group consisting of Parkinson's disease and Parkinsonian disorders, Huntington's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis, spinal ischemia, ischemic stroke, spinal cord injury and cancer-related brain/spinal cord injury.
93. The method of claim 90 wherein the disease or disorder of the central nervous system is selected from the group consisting of schizophrenia and other psychoses, depression, bipolar depression/disorder, anxiety syndromes/disorders, phobias, stress and related syndromes, cognitive function disorders, aggression, drug and alcohol abuse, obsessive compulsive behaviour syndromes, seasonal mood disorder, borderline personality disorder, Cerebral palsy, life style drug, multi-infarct dementia, Lewy body dementia, age related/geriatric dementia, epilepsy and injury related to epilepsy, spinal cord injury, brain injury, trauma related brain/spinal cord injury, anti-cancer treatment related brain/spinal cord tissue injury, infection and inflammation related brain/spinal cord injury, environmental toxin related brain/spinal cord injury, multiple sclerosis, autism, attention deficit disorders, narcolepsy and sleep disorders.

94. A host cell transformed or transfected with a molecule selected from the group consisting of SEQ ID NOs: 1, 2, 3 and 4.

95. The host cell of claim 94 which is a eukaryotic cell or a prokaryotic cell.

96. The host cell of claim 94 which is selected from the group consisting of a mammalian cell, a bacterial cell, a yeast.

97. A method of gene delivery and expression in a target cell of a mammal, comprising the step of introducing a viral vector into the target cell, wherein the viral vector has at least one insertion site containing a nucleic acid selected from the group consisting of SEQ ID NOs: 1, 2, 3 and 4, the nucleic acid gene operably linked to a promoter capable of expression in the host.

98. The method of claim 97, wherein the viral vector is a non-lytic viral vector.

99. A method of gene delivery and expression in a target cell of a mammal comprising the steps of:

- (a) providing an isolated nucleic acid fragment of sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3 and 4;
- (b) selecting a viral vector with at least one insertion site for insertion of the isolated nucleic acid fragment operably linked to a promoter capable of expression in the target cells;
- (c) inserting the isolated nucleic acid fragment into the insertion site, and
- (d) introducing the vector into the target cell wherein the gene is expressed at detectable levels.

100. The method of claim 99, wherein the virus is selected from the group consisting of retrovirus, adenovirus, and pox virus.

101. The method of claim 100, wherein the pox virus is vaccinia.

102. The method of claim 99, wherein the virus is selected from the group consisting of retrovirus, adenovirus, iridoviruses, coronaviruses, togaviruses, caliciviruses and picornaviruses.

103. The method of claim 99, wherein the virus is a strain that has been genetically modified or selected to be non-virulent in a host.

104. A method for alleviating a symptom of a disease or disorder of the central nervous system in a patient comprising the steps of:

- (a) providing a population of neural stem cells or neural progenitor cells;
- (b) suspending the neural stem cells or neural progenitor cells in a solution comprising a mixture comprising a growth factor dimer wherein each half of the dimer is selected from the group consisting of PDGF A, PDGF B, PDGF C, PDGF D, VGEF A, VGEF B, VGEF C, and VGEF D, to generate a cell suspension;
- (c) delivering the cell suspension to an injection site in the central nervous system of the patient to alleviate the symptom.

105. The method of claim 104 further comprising the step of injecting the injection site with the growth factor for a period of time before the step of delivering the cell suspension.

106. The method of claim 104 further comprising the step of injecting the injection site with said growth factor after said delivering step.

107. Use of PDGF, VEGF or a combination thereof, in the manufacture of a medicament for alleviating a symptom of a disease or disorder of the nervous system, wherein said medicament modulates neural stem cell or neural progenitor cell activity *in vivo* in a patient suffering from the disease or disorder of the nervous system

108. Use of an exogenous agent or antibody or affibody that is capable of modulating a PDGF receptor, VEGF receptor, or a combination thereof, on a neural stem cell or neural progenitor cell, in the manufacture of a medicament for inducing the neural stem cell or neural progenitor cell to proliferate or differentiate.

109. An *in vitro* method of drug screening and/or drug discovery using isolated samples from a non-human mammal, said method comprising:
comparing the effect of a PDGF or VEGF agonist on a first isolated sample taken from a non-human mammal to which said PDGF or VEGF agonist had been administered, with a second isolated sample taken from a non-human mammal to which the PDGF or VEGF agonist had not been administered.

110. Use of PDGF or VEGF or a PDGF agonist or VEGF agonist in the manufacture of a medicament for reducing a symptom of a disease or disorder of the central nervous system in a mammal in need of such treatment.

111. Use of PDGF or VEGF in the manufacture of a medicament for inducing *in situ* proliferation or differentiation of a neural stem cell or neural progenitor cell located in the neural tissue of a mammal.

112. Use of an expression vector containing a PDGF or VEGF gene, in the manufacture of a medicament for accelerating the growth of neural stem cells or neural progenitor cells in a desired target tissue in a subject, wherein said medicament is for intramuscular administration.

113. Use of PDGF, VEGF or PDGF or VEGF receptor agonist in the manufacture of a medicament for enhancing neurogenesis in a patient suffering from a disease or disorder of the central nervous system, wherein said medicament is for intraventricular infusion.

114. Use of PDGF in the manufacture of a medicament for increasing the number of dopaminergic neurons in a patient suffering from Parkinson's disease, wherein said medicament is for infusion into a lateral ventricle of the brain of the patient.

115. Use of an exogenous agent or antibody or affibody that is capable of activating a VEGF or PDGF receptor on a neural stem cell or neural progenitor cell, in the manufacture of a medicament for inducing a neural stem cell or neural progenitor cell expressing said receptor to proliferate or differentiate.

116. Use of the population of Claim 86, in the manufacture of a medicament for treating a disease or disorder of the central nervous system.
117. Use of a population of isolated primary neurons from a foetus, and a composition comprising PDGF or VEGF or PDGF agonist or VEGF agonist or a combination thereof, in the manufacture of a medicament for reducing a symptom of a disease or disorder of the central nervous system in a subject, wherein said medicament is for administration into the spinal cord of the subject.
118. Use of a viral vector in the manufacture of a medicament for gene therapy, wherein said vector has at least one insertion site containing a nucleic acid selected from the group consisting of SEQ ID NOs:1, 2, 3 and 4, and said nucleic acid gene is operably linked to a promoter capable of expression in the host.
119. Use of a cell suspension in the manufacture of a medicament for alleviating a symptom of a disease or disorder of the central nervous system in a patient, wherein said suspension comprises a population of neural stem cells or neural progenitor cells suspended in a solution containing a mixture containing a growth factor dimer wherein each half of the dimer is selected from the group consisting of PDGF A, PDGF B, PDGF C, PDGF D, VGEF A, VGEF B, VGEF C, and VGEF D, and wherein said medicament is for injection to a site in the central nervous system of the patient.



FIGURE 1**FIGURE 2**



FIGURE 3**FIGURE 4**


FIGURE 5**FIGURE 6**



FIGURE 7**FIGURE 8**

FIGURE 9



FIGURE 10



FIGURE 11



FIGURE 12




FIGURE 13

A.



B.




FIGURE 14




FIGURE 15





FIGURE 16






Fig. 17

~~Figure 1: Neurogenesis in the hippocampus is characterized by proliferative clusters of cells along the border between the granule cell layer (g) and the hilus region (h). These cells begin to migrate into the granule cell layer about 1 week after their last cell division and can be co-labeled with markers for granule cells (e.g. NeuN and Calbindin).~~
All Images by G. Kuhn.




Fig. 18

~~Figure 2: Flik-1 positive cells in the dentate gyrus. Frequently Flik-1 positive cells (green) are associated with clusters of proliferating cells. These clusters contain endothelial cells as well as neural stem cells/progenitors.~~
(A) Multiple immunofluorescence with BrdU, VEGF and Flik-1. Note the colocalization of Flik-1 and BrdU.
(B) BrdU positive cells are associated with blood vessels as shown with RECA staining (rat endothelial cell antigen)

~~All Images from Palmer et al., 2000.~~




Fig. 19

~~Figure 3: Localization of Flik-1 immunoreactive cells in the ventricle wall. The ependymal layer of the ventricle wall shows intense immunoreactivity for Flik-1. Since neural stem cells can be generated from ependymal cells of the ventricle wall, Flik-1 could function as a stem cell marker and has perhaps a function in stem cell recruitment. (Plate, Schänzer and Kuhn, unpublished data)~~




Fig. 20

Figure 4: Intracerebro-ventricular infusion of VEGF.
 VEGF was infused via osmotic minipumps for 7 days into the lateral ventricle of adult rats. Increased BrdU labeling in the granule cell layer of the dentate gyrus is observed 4 weeks after infusion of VEGF into the lateral ventricle. Plate, Schänzer, Cooper-Kuhn and Kuhn, unpublished data




Fig. 21

Figure 5. VEGF mRNA levels.
 Neurospheres wurden in definiertem Medium in Gegenwart von EGF und FGF kultiviert. Mittels RT-PCR wurde die mRNA dieser Zellen auf die Expression von 4 verschiedenen Isoformen von VEGF hin untersucht. GAPDH diente als Qualitätskontrolle für die mRNA. (Wachs, Wilhelm, Plate, Kuhn Manuskript in Vorbereitung).




Fig. 22

Figure 6: Flk-1 mRNA levels. Left. Neural stem cells from the lateral ventricle wall (LV) and hippocampus (HC) of the adult rodent can be grown as neurospheres using defined medium and the growth factors FGF-2 and EGF.
 Right. From spheres under growth condition mRNA was isolated and RT-PCR for Flk-1 was performed. Actin was used as a control for mRNA amount.




FIG. 23**FIG. 24****FIG. 25**

FIGURE 26




FIGURE 27






FIGURE 28**FIGURE 29**

FIGURE 30




FIGURE 31




FIGURE 32




FIGURE 33




FIGURE 34





FIGURE 35



INTERNATIONAL SEARCH REPORT

Intern: Application No
PCT/IB 02/03998

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/18 A61K48/00 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^o	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 040 157 A (CAO LIANG ET AL) 21 March 2000 (2000-03-21) column 30, line 36-49 column 32, line 21-27 column 27, line 38 column 38, line 7-13 column 39, line 3-12 ---	1-119
X	WO 99 47677 A (GENENTECH INC) 23 September 1999 (1999-09-23) page 71, line 22-36 ---	1-119 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

22 January 2003

Date of mailing of the international search report

10.02.2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

IDA CHRISTENSEN / ELY

INTERNATIONAL SEARCH REPORT

Inter I Application No
PCT/IB 02/03998

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 37751 A (IMCLONE SYSTEMS INC ;MOORE MALCOLM A S (US); SLOAN KETTERING INST) 29 July 1999 (1999-07-29) page 5, line 13-15 page 15, line 3-5 page 15, line 8-10 the claims ---	1-119
X	EP 1 132 098 A (MORISHITA RYUICHI ;MEDGENE BIOSCIENCE INC (JP)) 12 September 2001 (2001-09-12) the claims ---	1-119
X	WO 01 49849 A (ZYMOGENETICS INC) 12 July 2001 (2001-07-12) page 57, line 1-7 page 39, line 28-32 page 40, line 22-24 ---	36-47, 53,56, 60, 64-66, 69,72, 77-79, 90-93, 108-110, 113,115, 117
X	GRINSPAN J B ET AL: "Protein growth factors as potential therapies for central nervous system demyelinative disorders." ANNALS OF NEUROLOGY, vol. 36, no. SUPPL., 1994, pages S140-S142, XP002228189 ISSN: 0364-5134 abstract ---	1-119
X	VALENZUELA C FERNANDO ET AL: "Roles of platelet-derived growth factor in the developing and mature nervous systems." BRAIN RESEARCH REVIEWS, vol. 24, no. 1, 1997, pages 77-89, XP002228190 ISSN: 0165-0173 page 84, column 2 ---	1-119
P,X	WO 01 76620 A (VLAAMS INTERUNIVERSITAIR INST ;COLLEN DESIRE (BE); CARMELIET PETER) 18 October 2001 (2001-10-18) the claims ---	1-119
	-/-	

INTERNATIONAL SEARCH REPORT

Intern'l Application No

PCT/IB 02/03998

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	KWON YUNHEE KIM: "Effect of neurotrophic factors on neuronal stem cell death." JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 35, no. 1, 31 January 2002 (2002-01-31), pages 87-93, XP002228191 ISSN: 1225-8687 the conclusion -----	1-119
A	US 5 653 975 A (BAETGE EDWARD E ET AL) 5 August 1997 (1997-08-05) column 1, line 65 -column 2, line 20 the claims column 19, line 31-36 -----	1-119

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 02/03998

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: **1-68, 79-84, 87, 90-93, 97-104**
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.: **11-12**
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-119

Invention 1: claims 1-119 (partially)

The use of PDGF for the treatment of a disease or disorder of the nervous system.

Invention 2: claims 1-119 (partially)

The use of VEGF for the treatment of a disease or disorder of the nervous system.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 1-68,79-84,87,90-93,97-104

Claims 1-68,79-84,87,90-93,97-104 relate to methods of treatment of the human or animal body by surgery or by therapy, or diagnostic methods practised on the human or animal body (Rule 39.1(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

Continuation of Box I.2

Claims Nos.: 11-12

Present claims 11-12 relate to a large number of possible diseases or disorders of the nervous system. Support within the meaning of Article 6 PCT and / or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the disorders claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for disorders of the nervous system in general, and more specifically for Parkinson's disease.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Application No.

PCT/IB 02/03998

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 6040157	A	21-03-2000	US	5932540 A	03-08-1999
			US	5935820 A	10-08-1999
			AU	3072099 A	27-09-1999
			CA	2322748 A1	16-09-1999
			CN	1299407 T	13-06-2001
			EP	1062319 A1	27-12-2000
			JP	2002505873 T	26-02-2002
			WO	9946364 A1	16-09-1999
			US	2002182683 A1	05-12-2002
			AU	714484 B2	06-01-2000
			AU	6046796 A	24-12-1996
			CA	2224093 A1	12-12-1996
			CN	1186518 A	01-07-1998
			EP	0837934 A1	29-04-1998
			JP	2000069982 A	07-03-2000
			JP	11513883 T	30-11-1999
			WO	9639515 A1	12-12-1996
			US	2002120123 A1	29-08-2002
			AU	696764 B2	17-09-1998
			AU	7394194 A	25-09-1995
			CA	2184584 A1	14-09-1995
			CN	1145636 A	19-03-1997
			EP	0751992 A1	08-01-1997
			JP	9510093 T	14-10-1997
			WO	9524473 A1	14-09-1995
			ZA	9403464 A	20-11-1995
WO 9947677	A	23-09-1999	US	6391311 B1	21-05-2002
			AU	3072199 A	27-09-1999
			AU	3075099 A	11-10-1999
			CA	2322792 A1	23-09-1999
			EP	1064382 A2	03-01-2001
			US	2002094416 A1	18-07-2002
			WO	9946281 A2	16-09-1999
			WO	9947677 A2	23-09-1999
			US	6455283 B1	24-09-2002
			US	2003004102 A1	02-01-2003
			US	2002177553 A1	28-11-2002
			US	2002156006 A1	24-10-2002
			US	2002169284 A1	14-11-2002
WO 9937751	A	29-07-1999	US	2002051762 A1	02-05-2002
			AU	2469299 A	09-08-1999
			CA	2311729 A1	29-07-1999
			EP	1060242 A1	20-12-2000
			JP	2002500879 T	15-01-2002
			WO	9937751 A1	29-07-1999
EP 1132098	A	12-09-2001	AU	7314800 A	24-04-2001
			EP	1132098 A1	12-09-2001
			CN	1322143 T	14-11-2001
			WO	0121214 A1	29-03-2001
WO 0149849	A	12-07-2001	AU	2631001 A	16-07-2001
			WO	0149849 A1	12-07-2001
WO 0176620	A	18-10-2001	AU	6896801 A	23-10-2001
			WO	0176620 A2	18-10-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

Interr	I Application No
PCT/IB	02/03998

Patent document cited in search report	Publication date		Patent family member(s)		Publication date
WO 0176620	A	EP	1272208 A2		08-01-2003

US 5653975	A 05-08-1997	AT	218893 T		15-06-2002
		AU	7568094 A		14-03-1995
		AU	717663 B2		30-03-2000
		AU	9718498 A		04-03-1999
		CA	2169292 A1		23-02-1995
		DE	69430824 D1		18-07-2002
		DK	802800 T3		07-10-2002
		EP	1179350 A2		13-02-2002
		EP	0802800 A2		29-10-1997
		FI	960611 A		09-04-1996
		JP	9508002 T		19-08-1997
		NO	960547 A		12-04-1996
		SG	48813 A1		18-05-1998
		WO	9505452 A2		23-02-1995
		US	6264941 B1		24-07-2001
		US	5639275 A		17-06-1997
		US	5656481 A		12-08-1997
		US	5676943 A		14-10-1997
		US	5908623 A		01-06-1999